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V. Summary 
 
Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal lung disease of 
unknown origin, characterized by alveolar epithelial cell damage, increased deposition of 
extracellular matrix (ECM) in the lung interstitium, enhanced fibroblast/myofibroblast 
proliferation and activation, which ultimately lead to distortion of normal lung 
architecture and loss of respiratory function. While the initial trigger of this disease is 
most likely an epithelial injury, the interstitial fibroblast/myofibroblast represents the key 
effector cell responsible for the increased ECM deposition characteristic of IPF. 
Fibroblasts secrete large amounts of fibrillar collagens, which are the key ECM proteins 
that are significantly increased in this disease. L-arginine is a precursor of many active 
compounds including: nitric oxide, asymmetrical dimethylarginine, and praline, an amino 
acid that is enriched in collagen. Thus, it was hypothesized that L-arginine metabolism is 
altered in pulmonary fibrosis, ultimately affecting collagen synthesis. 
In this study, the expression of key enzymes of the L-arginine pathway was 
characterized in bleomycin-induced pulmonary fibrosis in mice. Expression of arginase-1 
and arginase-2 was significantly upregulated during bleomycin-induced lung fibrosis, 
which correlated with a decrease in lung L-arginine levels, as measured by high 
performance liquid chromatography. Furthermore, arginase-1 and arginase-2 mRNA and 
protein expression localized to fibroblasts, and their expression was increased in primary 
fibroblasts isolated from bleomycin-treated mice, compared to controls, as assessed by 
semi-quantitative and quantitative RT-PCR, and immunoblotting. Moreover, TGF-β1, 
a key profibrotic mediator, induced arginase-1 mRNA expression in primary and 
NIH-3T3 fibroblasts. Finally, treatment of NIH-3T3 fibroblasts and primary human lung 
fibroblasts with the arginase inhibitor, NG-hydroxy-L-arginine, attenuated TGF-β1-
stimulated collagen deposition, but not Smad signaling. Arginase-1 and arginase-2 
mRNA expression, as well as their activity, however, was unchanged in total human lung 
homogenates from IPF patients compared to controls.  
These results demonstrated that arginase isoforms, key enzymes in nitric oxide 
and collagen metabolism, were expressed and functional in lung fibroblasts and 
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upregulated in the early stages of bleomycin-induced pulmonary fibrosis. These changes 
were limited to the animal model of pulmonary fibrosis, as no changes in expression were 
observed in lungs from IPF patients. The TGF-β1-induced upregulation of arginase-1 
suggested an interplay between profibrotic agents and L-arginine metabolism during the 
course of experimental lung fibrosis, therapeutic manipulation of which may foster novel 
treatment options. 
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VI. Zusammenfassung 
 
Die Idiopathische Lungenfibrose (Idiopathic pulmonary fibrosis – IPF) ist eine 
progrediente und fatale Lungenerkrankung unbekannten Ursprungs. Sie ist 
gekennzeichnet durch eine Schädigung der alveolären Epithelzellen, vermehrter 
Ablagerung von extrazellulärer Matrix im Interstitium der Lunge, verstärkter 
Proliferation und Aktivierung von Fibroblasten bzw. Myofibroblasten, was schließlich zu 
einer Zerstörung des normalen Gewebes führt, sowie zum Verlust der Lungenfunktion. 
Während die Krankheit initial höchstwahrscheinlich durch eine Verletzung es 
Lungenepithels ausgelöst wird, gelten die Fibroblasten bzw. die Myofibroblasten als 
Schlüsselzellen, da sie für die charakteristische Ablagerung extrazellulärer Matrix 
während des Krankheitsverlaufes der IPF verantwortlich sind. Fibroblasten produzieren 
große Mengen an fibrillärem Kollagen, welches die Hauptkomponenten der 
Extrazellulären Matrix darstellen, die bei der Lungenfibrose signifikant erhöht 
vorkommen. L-Arginin ist eine wichtige biologische Vorstufe vieler aktiver 
Verbindungen, wie zum Beispiel Stickoxid, asymmetrisches Dimethylarginin, und Prolin 
– einer Aminosäure, die besonders häufig in Kollagen vorkommt. Daher stellten wir die 
Hypothese auf, dass der L-Arginin-Metabolismus in der Lungenfibrose verändert ist, was 
schließlich die Kollagensynthese in Fibroblasten beeinflusst.  
In dieser Studie wurde die Expression der Schlüsselenzyme des L-Arginin-
Stoffwechselwegs während der Bleomycin-induzierten Lungenfibrose in Mäusen 
untersucht. Arginase-1 und Arginase-2 waren während der Bleomycin-induzierten 
Lungenfibrose signifikant hochreguliert, was mit einer gleichzeitigen Verringerung der 
L-Arginin-Level in der Lunge, gmessen mit high performance liquid chromatography 
(HPLC), einherging. Weiterhin war die Arginase-1 und Arginase-2 in den Fibroblasten 
exprimiert und war in primären Fibroblasten, isoliert aus Bleomycin-behandelten Mäusen 
im Vergleich zu unbehandelten Kontrollen, erhöht. Interessanterweise induzierte 
TGF-β1, ein profibrotischer Schlüsselmediator, die Arginase-1 mRNA-Expression in 
primären Fibroblasten und in NIH3T3-Zellen. Schließlich verringerte eine Behandlung 
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von NIH3T3-Fibroblasten sowie humaner Lungenfibroblasten mit dem Arginase-
Inhibitor NG-hydroxy-L-arginin die TGF-β1-induzierte Kollagenablagerung, jedoch nicht 
die Signaltransduktion durch Smads. Die mRNA-Expression von Arginase-1 und 
Arginase-2, sowie deren Aktivitäten zeigten jedoch in Lungenhomogenaten von 
Fibrosepatienten im Vergleich zu gesunden Kontrolllungen keine Veränderung. 
Diese Ergebnisse zeigen, dass Isoformen der Arginase, die Schlüsselenzyme im 
Stickoxid- und im Kollagenstoffwechsel sind, in Lungenfibroblasten exprimiert werden 
und funktional von Bedeutung sind. Dies konnte im Tiermodell gezeigt werden, während 
keine Veränderungen der Expression in Lungen von Fibrosepatienten festgestellt wurden. 
Die TGF-β1-induzierte Hochregulierung von Arginase-1 deutet auf eine Wechselwirkung 
zwischen profibrotischen Molekülen und dem L-Arginin-Metabolismus während des 
Verlaufs der experimentellen Lungenfibrose hin, welche ein Ansatzpunkt für eine 
Entwicklung neuer medizinischer Behandlungsmethoden darstellen könnte.  
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1. Introduction 
1.1. Idiopathic pulmonary fibrosis 
1.1.1. Characteristics of idiopathic pulmonary fibrosis 
Idiopathic pulmonary fibrosis (IPF), also referred to as cryptogenic fibrosing 
alveolitis, is a progressive and fatal lung disease of unknown etiology 1. In principal, IPF 
is characterized by alveolar epithelial cell damage, increased deposition of extracellular 
matrix (ECM) in the lung interstitium, and enhanced fibroblast/myofibroblast 
proliferation and activation. These processes ultimately lead to distortion of normal lung 
architecture and loss of respiratory function 2. 
Idiopathic pulmonary fibrosis is a relatively rear lung disorder with prevalence 
rate of three to six cases per 100 000 individuals with, mean survival ranging from two to 
four years after diagnosis 3. It is also reported that IPF is more common amongst men 
than women 4. The disease occurs predominantly from middle age onwards, with patients 
usually between 50 to 70 years of age at presentation. Two thirds of the patients are older 
than 60 years, which makes prognosis poor, since both incidence and death rate increase 
with age 5. Although IPF affects millions of individuals worldwide, there is still no 
effective therapeutic approach, and so far, lung transplantation is the only viable option 
for patients that are refractory to medical therapy.  
Since the pathogenesis of IPF is complex and poorly understood, identification of 
risk factors that may contribute to the development of the disease is essential. Although 
cigarette smoking 6, the presence of several viruses 7-9, and environmental factors 10,11 
have been suggested to increase the risk of developing IPF, their impact remains to be 
fully elucidated. Some reports have speculated that genetic factors may contribute to the 
familial cases of pulmonary fibrosis, nevertheless, no specific genetic abnormalities have 
been identified to date 12,13. While the cause of IPF remains unknown, advances in 
cellular and molecular biology have extended our understanding of the biological 
processes involved in the initiation and progression of this disease. 
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1.1.2. Histopathology of idiopathic pulmonary fibrosis 
Idiopathic pulmonary fibrosis is characterized histologically by features of usual 
interstitial pneumonia (UIP) that include alveolitis, disruption of the pulmonary vascular 
bed, and fibrosis of the pulmonary parenchyma. The histological hallmark of this disorder 
is a heterogeneous appearance of the normal lung alternating with areas of interstitial 
inflammation, peripheral fibrosis and honeycomb changes 4,14. Usually the peripheral 
subpleural parenchyma is most severely affected by these histopathologic changes. 
Inflammatory components observed in the lungs of patients with IPF typically consist of 
lymphocytes and plasma cells, and to some extent eosinophiles and neutrophils. Clusters 
of fibroblasts/myofibroblasts can be observed at the borders between fibrotic and normal 
lung, they create so called fibrotic foci. Moreover, alveolar epithelial injury with 
hyperplasia of type II pneumocytes is often seen in areas of active fibrosis 14. Dense 
fibrosis leads to scaring and lesions followed by architectural destruction of the lung and 
the resultant loss of its respiratory function (Figure 1.1.).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1. Histopathological changes in the lung in IPF. 
Structure of the lung in a healthy donor (left) and in a patient with IPF (right). Paraffin 
embedded sections stained for α-smooth muscle actin, and with hematoxylin and eosin.  
DONOR IPF 
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1.1.3. Pathogenesis of idiopathic pulmonary fibrosis 
The pathogenesis of IPF is complex and poorly understood. Several studies have 
been performed to elucidate pathogenic mechanisms that are involved in this disease. 
From these attempts, two hypotheses of IPF pathogenesis have arisen. The original 
so-called “old” hypothesis asserts that unknown stimuli injure the lung resulting in 
chronic inflammation which triggers fibrogenesis followed by the end-stage fibrotic 
scar 15 (Figure 1.2.A.). Idiopathic pulmonary fibrosis was believed to be a process of 
chronic repair that resulted from persistent inflammation accompanied by activation of 
inflammatory cells and the presence of cytokine and growth factors, which lead to 
activation of mesenchymal cells, with enhanced matrix deposition 16.  
 
 
Figure 1.2. Representation of the two hypotheses of IPF pathogenesis. 
The (A) old, and (B) new hypothesis of the pathogenesis of idiopathic pulmonary 
fibrosis. 
 
However, this hypothesis had to be revised as more detailed subsequent studies 
revealed that inflammatory processes were mild in lung biopsies from patients with IPF, 
and occured mainly in areas of collagen deposition and honeycombing 17. Moreover, the 
role of inflammation at early stages of IPF is not clear, since little evidence supported the 
concept that inflammation is more prominent during the onset of the disease. 
Additionally, there are no data describing the early phase of IPF, since the histology of 
patients presenting with IPF, both at six months and at two years after recognition of 
B. 
REPETITIVE STIMULUS 
EPITHELIAL INJURY 
IMPAIRED HEALING 
FIBROSIS 
GENETIC 
FACTOR
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A. 
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symptoms, exhibits variable degrees of fibrosis and honeycombing with mild to moderate 
inflammation 2. Furthermore, the lack of effect of anti-inflammatory drugs in patients 
with IPF also suggested that inflammation may not be the driving force in IPF 3,18.  
On the basis of this evidence, it has been proposed that IPF results from sequential 
alveolar epithelial injury and abnormal wound repair 15,17. According to this “new” 
hypothesis, epithelial injury and activation rather than alveolitis is the key factor in this 
disease 19 (Figure 1.2.B.). Alveolar epithelial cell injury induces the proliferation of 
fibroblasts and their differentiation in to myofibroblasts. The activated interstitial 
fibroblasts/myofibroblasts represent effector cells responsible for the increased ECM 
deposition characteristic of the disease 5,20.  
 
 
1.1.4. Animal models of pulmonary fibrosis 
Several animal models of pulmonary fibrosis have been developed in order to 
better understand the mechanism and pathogenesis of IPF. Despite a number of 
exogenously administered agents that can induce pulmonary fibrosis in a variety of 
animal species (Table 1.1.) 21, data indicate discrepancies between animal models of 
pulmonary fibrosis and human IPF. Although an ideal experimental animal model of this 
disease remains elusive, over last three decades, the bleomycin model has been at the 
forefront of basic research into the regulation of pulmonary fibrosis.  
 
Table 1.1. Approaches for inducing pulmonary fibrosis in animal models 21. 
 
Exogenous agent/ 
Approach 
Nature of tissue damage Animal species used 
Bleomycin Oxidant-mediated DNA scission leading to fibrogenic cytokine release 
Mice, rats, hamsters, rabbits, 
dogs, primates, pheasants 
Inorganic particles (silica) Hypersensivity reactions with or without granuloma formation 
Mice, rats, hamsters, rabbits, 
sheep 
Irradiation Free radical-mediated DNA damage Mice, rats, hamsters, rabbits, dogs, sheep, primates 
Gene transfer (TGF-β, 
IL-1β) 
Downstream activation of specific cytokine 
pathways Mice, rats 
Fluorescein isothiocyanate Incompletely understood. Presumed T-cell-independent Mice 
Vanadium pentoxide Incompletely understood. An inorganic 
metal oxide. Mice, rats 
Haptenic antigens  Recall cell-mediated immune response Mice, hamsters 
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Bleomycin is an antibiotic agent with antitumor activity, originally isolated from 
Streptomyces verticillus. It is used as a part of cytostatic treatment of several tumors such 
as germ-cell tumors, lymphomas, Kaposi’s sarcoma, cervical cancer, and squamous cell 
carcinomas of head and neck 22. It exerts a cytotoxic effect by induction of free radicals 
that cause DNA breaks leading ultimately to cell death 23. Bleomycin is eliminated 
primarily by the kidneys, and further deactivation of this agent can be carried out by 
bleomycin hydrolyse, an enzyme expressed in the liver, spleen, bone marrow and 
intestine 24. Due to the lack of this enzyme in the lungs and the skin, bleomycin-induced 
toxicity is predominantly observed in these organs. 
Bleomycin-induced lung fibrosis was observed in mice, rats, hamsters, rabbits, 
dogs, primates and pheasants. The bleomycin model is characterized by biochemical and 
functional features that closely resemble those found in human pulmonary fibrosis. 
Among these features are: alveolar epithelial cell damage, recruitment of inflammatory 
cells releasing mediators of inflammation, abnormal fibroblast activation and 
proliferation, increased deposition of ECM in the interstitium and alveolar space, leading 
to a reduction of lung volume and poor compliance 19.  
Although the bleomycin model is the most frequently employed model to study 
the pathogenesis of lung fibrosis, it has several limitations. Multiple studies have pointed 
out the differences between this model and human IPF including the speed of onset – as 
the remodeling is accelerated in bleomycin induced pulmonary fibrosis, durability – as in 
the model of fibrosis in its chronic stage may develop focal emphysema-like changes 16. 
Moreover, administration of bleomycin leads to pneumonitis/fiborsis, which is reversible 
with steroids, whereas progression of IPF is influenced by these agents only to a limited 
extent 21. Despite its limitations, the bleomycin model represents a promising approach to 
examine the molecular players involved in the pathogenesis of IPF.  
 
 
1.1.5. Fibroblasts: key effector cells in fibrogenesis 
Fibroblasts belong to the connective tissue cell family. They are able to undergo 
various phenotypic conversions. This phenotypic plasticity is an important feature of the 
response to many types of tissue injury 25. The main role of fibroblasts is in the repair and 
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regenerative processes in every tissue and organ. This primary function is achieved by 
secretion of ECM proteins that provide a tissue scaffold for normal repair processes 
course such as epithelial cell migration. Importantly, final dissolution of this scaffold and 
apoptosis of fibroblasts/myofibroblasts seem to be pivotal for restoration of the normal 
tissue architecture 26.  
A number of studies have reported that alveolar epithelial cells may initiate the 
pathogenic processes in IPF by production of the active mediators affecting fibroblasts 
which induce phenotypic changes in these cells during the progression and end-stage of 
fibrosis 17,27 (Figure 1.3.) 2. The presence of these activated fibroblasts with myofibroblast 
phenotype was described in fibroblastic foci which suggested a role in disease 
development (Figure 1.4.) 15,17. In normal repair and regenerative processes, activated 
fibroblasts produce contractile proteins which are crucial in the re-epithalization events, 
since they bring the wound closer together 26. In addition, these cells have the capacity to 
produce ECM proteins, growth factors, growth factor receptors, cytokines, integrins and 
oxidants 28,29. It has been proposed that programmed cell death mediates the decrease in 
the number of mesenchymal cells finally, allowing differentiation of other cell types to 
reestablish tissue.  
 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. The primary pathogenic events in IPF. 
Unknown injury causes activation of alveolar epithelial cells that release factors inducing 
migration and proliferation of fibroblasts and changes in their phenotype. In the lesion, 
myofibroblasts can induce epithelial cell apoptosis and disruption of basement membrane 
which leads to abnormal re-epithalization. Activated fibroblasts and myofibroblasts 
secrete excessive amounts of ECM 2. 
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Several studies have attempted to characterize the phenotype of fibroblasts in IPF 
in a more detailed manner. However, these studies have generated conflicting results. 
According several studies, fibroblasts first assume a migratory phenotype, then 
a proliferative phenotype, and finally a profibrotic phenotype, during which they produce 
abundant ECM components. Moreover, there are reports suggesting that fibroblasts from 
IPF lungs induce alveolar epithelial cell death, wich leads to the abnormal wound healing 
observed in this disease 30. The repair failure of the damaged alveolar epithelium cells is 
not only directly caused by fibroblasts, but also indirectly by the degenerative affects of 
fibroblasts on the basement membrane. The basement membrane is a complex structure 
that includes type IV collagen, laminin, entactin, fibronectin, and heparin sulfate-
chondroitin proteogylcans 31. In IPF, fibroblasts/myofibroblasts contribute to the 
degeneration of this complex structure by production of gelatinases A and B, enzymes 
that degrade components of the membrane 32. Disrupted basement membrane can no 
longer play a dynamic role in maintaining the integrity and differentiation of the alveolar 
epithelium. Moreover, under this condition, the migration of fibroblasts and 
myofibroblasts into the alveolar space is facilitated 33. 
Fibroblasts and myofibroblasts have key functions in the synthesis, deposition, 
and remodeling of the ECM. Increased ECM deposition, including fibrillar collagens, 
fibronectin, elastic fibers, and proteoglycans, is the hallmark of the abnormal tissue 
remodeling in IPF 14,34.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. Fibroblast foci in IPF lung. 
Fibroblasts foci are indicated with arrows. Hematoxylin and eosin staining 15,17. 
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1.1.6. Collagen – a key compound of the extracellular matrix 
Collagen fibrils are the key ECM proteins that display significantly increased 
levels in IPF 35. The fibrils are synthesized and secreted by fibroblasts but how this 
process is controlled during regeneration and tissue repair remains poorly understood. 
Collagens are trimeric molecules in which each chain consists of repeating Gly-X-Y 
triplets, where X and Y are usually proline and hydroxyproline, respectively 36. This 
triplet motif results in a left-handed helix that, together with two other helices, can form 
a right-handed triple-helical structure that (dependent on collagen type) can be 
homotrimeric or heterotrimeric 37. Until now, 27 different collagen types have been 
identified.  
Biosynthesis of collagen is a complex process that requires the formation of 
procollagen, which undergoes extensive post-translational modification. These 
modifications occur prior to triple helix formation, and consist of hydroxylation of 
proline and lysine. Hydroxylation of L-proline occurs in an ascorbic acid-dependent 
manner and is essential for collagen stability 36. L-proline is generated sequentially from 
L-ornithine and L-arginine by a set of highly regulated enzymes. Therefore, the 
abundance of L-arginine, as well as the expression of enzymes metabolizing this amino 
acid, represent essential determinants of L-proline supply 38-40 and may be a limiting 
factor in the process of fibrosis. It has been reported that L-arginine becomes essential for 
growth and development in post-traumatic situations 41. L-arginine enhances wound 
healing wich also suggests its involvement in collagen metabolism. 
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1.2. L-arginine metabolism 
1.2.1. L-arginine physiology 
L-arginine is a proteinogenous basic amino acid that carries guanidinium groups 
on its side chains, and has positive charge at neutral pH. In animals, L-arginine is 
classified as semi-essential amino acid that can be synthesized by several pathways 39. 
However, in cases of immaturity, disease or injury, endogenous production of this amino 
acid may be insufficient to meet higher demand. L-arginine is one of the most 
metabolically versatile amino acids in animal cells. It serves as a precursor for the 
synthesis of a vast range of substances including urea, nitric oxide, polyamines, proline, 
glutamate, and creatine 42. 
Given its diverse roles, L-arginine is metabolized by a complex and highly 
regulated set of enzymes in several pathways that remain to be explored in more detailed 
manner. It is known that intracellular L-arginine concentrations may, to some extent, 
affect the expression of L-arginine metabolic enzymes. By its diversity of function, 
L-arginine can modulate immune function 43, wound healing 44, hormone secretion 45, 
vascular tone 46, insulin sensitivity 47, and endothelial function 48.  
 
 
1.2.2. L-arginine synthesis and transport  
The sources of L-arginine in the body are dietary proteins, endogenous synthesis, 
and protein turnover. The majority of plasma L-arginine is derived from protein 
metabolism and turnover, whereas de novo synthesis accounts for only 5–15 % of the 
endogenous supply. Three organs are involved in the synthesis of this amino acid: the 
small intestine, the kidneys, and the liver 38,49.  
Glutamine, and glutamate are the dietary amino acids which are metabolized in 
the small intestine and serve as major precursors for intestinal synthesis of L-arginine or 
citrulline. From the intesitine, citrulline is transported to the kidney, where it is converted 
into L-arginine by the action of two metabolic enzymes: argininosuccinate synthase 
(ASS) and, argininosuccinate lyase (ASL). Approximately 60 % of net arginine synthesis 
in adult mammals occurs in the kidney 50,51 (Figure 1.5.) 39. 
Introduction  10 
8 
7 
6 
 
5 
11 
4 
 
3 
2 
1 
L-glutamine 
L-glutamate 
L-glutamyl-γ-phosphate 
L-glutamyl-γ-semialdehyde 
L-proline 
L-ornithine 
L-citrulline 
L-argininosuccinate 
L-arginine 
2-oxoglutarate 12 
CP HCO3-+NH3 
10 
N-actylglutamate 
L-glutamate 
9 L-∆
1
-pyrroline-5-carboxylate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5. Pathways of arginine synthesis. 
Enzymes catalyzing indicated reactions are: 
1, phosphate-dependent glutaminase; 2 and 3, L-∆1-pyrroline-5-carboxylate (P5C) 
synthetase; 4, spontaneous step; 5, ornithine amintransferase (OAT); 6, ornithine 
carbamoyltransferase (OCT); 7, argininosuccinate synthase (ASS); 8, argininosuccinate 
lyase (ASL); 9, N-acetylglutamate synthase; 10, carbamoyl-phosphate synthase I (CPS I); 
11, proline oxidase; 12, aspartate aminotransferase 39. 
 
 
The synthesis of L-arginine also occurs within the hepatic urea cycle 52, which is 
localized in periportal hepatocytes. This process is possible in the liver only when all the 
necessary intermediates of the urea cycle, including ornithine, are present. The 
components of the urea cycle are so closely organized within hepatocytes that 
intermediates generated within the pathway are immediately utilized and thus do not 
freely exchange with intracellular pools 53. 
Moreover, in non-hepatic cells, citrulline is co-produced with nitric oxide (NO), 
and can be recycled to L-arginine via the so-called citrulline/NO cycle or 
arginine/citrulline cycle. This recycling process is accomplished by the action of ASS and 
ASL, which are expressed in nearly all cell types (Figure 1.6.) 39. 
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Figure 1.6. The citrulline/NO cycle 39. 
Co-production of L-citrulline and NO can be coupled to the citric acid cycle presented on 
the right. Fumarate produced in the cytosol enters the citric acid cycle in the 
mitochondrion, where it is converted into oxaloacetate. Oxaloacetate by transamination is 
converted to aspartate, which is transported into the cytosol. Enzymes catalyzing 
indicated reactions are: 1, fumarase; 2, malate dehydrogenase; 3, aspartate 
aminotransferase. Reactions 1-3 are reversible, what is not depicted on the diagram for 
the sake of simplicity. Argininosuccinate lyase (ASL), argininosuccinate synthase (ASS), 
nitric oxide synthase (NOS) 39. 
 
 
 
Substrate availability for arginine-requiring enzymes is not only regulated by the 
level of this amino acid, but also by the arginine transport system. In the majority of 
mammalian cells, L-arginine requirements are primarily met by the uptake of 
extracellular L-arginine via specific transporter systems including the y+, b0,+, B0,+, and 
transporters y+L 54. Not every cell type expresses all of these transporters, but their 
expression and activity can be induced and dynamically regulated by diverse stimuli, 
such as bacterial endotoxins or inflammatory cytokines 55,56. System y+ is considered to 
be the most important in the uptake of L-arginine in most cell types. It is a high-affinity, 
Na+-independent transporter of not only arginine, but also for ornithine and lysine 57. 
However, other cationic amino acids and positively-charged analogs can effectively 
inhibit L-arginine uptake by this system. The y+ system, as with the other arginine 
transport systems, displays diverse expression levels among different cell types and can 
be dynamically regulated at the pretranslational level 39. For instance, this system is 
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present in many cell types, although is absent from hepatocytes. Nevertheless, its 
expression can be efficiently induced in these cells by inflammatory cytokines 58. 
Additionally, expression of this system is reported to be co-induced by inducible nitric 
oxide synthase (iNOS) in wide variety of cell types, which suggests that an increase in 
L-arginine transport capacity supports the elevated NO synthesis. 
 
 
1.2.3. L-arginine catabolism 
L-arginine can be catabolized via multiple pathways. In contrast to a single 
enzyme that produces L-arginine, four sets of enzymes use this amino acid as a substrate 
in mammalian cells: nitric oxide synthase (NOS), arginase (ARG), arginine:glycine 
amidinotransferase (AGAT), and arginine decarboxylase (ADC). With the exception of 
ADC, all of these enzymes act on the guanidine group of L-arginine. Some of these 
enzymes have multiple isoforms, which leads to a high complexity of L-arginine 
metabolism. There are three distinct isoforms of NOS: neuronal (nNOS), inducible 
(iNOS), endothelial (eNOS); and two isoforms of ARG (type 1 and 2).  
The metabolic complexity extends further as the product of one enzyme may 
inhibit the activity of another. Moreover, the cellular distribution of enzyme expression 
varies widely. Some of these enzymes can be coexpressed within the same cell, whereas 
others are highly restricted to a specific subcellular compartment. For instance, almost all 
cells can express iNOS upon appropriate stimuli 59, whereas expression of AGAT is 
limited to kidney, pancreas, and liver 60. The activity of ADC as well as ARG2 was 
reported in mitochondria of many different cell types, in contrast to ARG1 which is 
a cytosolic enzyme localized to the liver. The overview of the L-arginine catabolic 
pathway is presented in a simplified scheme in (Figure 1.7.) 38. 
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Figure 1.7. Arginine metabolic pathways.  
For the sake of clarity, only enzymes that directly use or produce arginine, ornithine or 
citrulline are indicated, and not all reactants and products are depicted. Inhibition of nitric 
oxide synthase (NOS) and arginase (ARG) by asymmetric dimethylarginine (ADMA) 
and NG-hydroxy-L-arginine (NOHA), respectively, are illustrated by the dashed lines and 
dash within a circle. Amino acid residues within proteins are indicated by brackets. 
Arginine decarboxylase (ADC), arginine:glycine amidinotransferase (AGAT), arginase 
(ARG), argininosuccinate lyase (ASL), argininosuccinate synthase (ASS), 
dimethylarginine dimethylaminohydrolase (DDAH), dimethyl (Me2), nitric oxide (NO), 
ornithine aminotransferase (OAT), ornithine transcarbamylase (OTC), protein arginine 
methyltransferase (PRMT) 38. 
 
 
Arginine:glycine amidinotransferase is a mitochondrial enzyme that takes part in 
a well-known pathway, where it initiates the synthesis of creatine. This enzyme transfers 
the guanidino group from L-arginine to glycine, to form guanidineacetate and 
ornithine 61. It is present mainly in renal tubules and pancreas but also to a lesser extent in 
the liver and other organs. The catabolism of L-arginine through AGAT is determined by 
dietary levels of creatine, which acts as a feedback repressor of this enzyme 62. 
The existance of ADC in mammalian cells was for a long time controversial. It 
was reported to be present in plants and bacteria, but it was thought to be absent in 
mammalian cells. Its activity was subsequently identified in the brain, liver, kidney, 
adrenal gland, macrophages, and the small intestine 63-65. However, the presence and 
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activity of this enzyme remains somewhat unclear since recent reports have challenged 
previous conclusions. Nevertheless, this enzyme was shown to convert L-arginine to CO2 
and agmatine, and it was demonstrated to be localized in the mitochondrial fraction of 
cell homogenates 66. 
Arginase is a central enzyme in L-arginine metabolism as it facilitates 
downstream conversion of this amino acid to urea, ornithine, proline, polyamines, 
glutamate, or glutamine. There are two distinct types of mammalian ARG: ARG1 
(type 1) and ARG2 (type 2), which are encoded by independent genes. Both enzymes are 
similar with respect to their enzymatic activity, but different with regard to subcellular 
and tissue localization, and regulation of expression 67. Arginase-1 is a cytosolic enzyme 
mainly expressed in the liver as a component of urea cycle, where it converts arginine to 
ornithine and urea. In limited amounts it is also expressed in other organs. Arginase-2, on 
the contrary, is a mitochondrial enzyme, expressed in many organs including the kidney, 
brain, small intestine, mammary gland, and in endothelium and macrophages 67-70. 
Differential isoenzymes expression patterns could be explained by the fate of synthesized 
ornithine, preferentially directed either to proline or glutamate synthesis via ornithine 
aminotransferase (OAT), or to polyamine synthesis via ornithine decarboxylase 
(ODC) 39. 
The family of NOS isoenzymes is the best characterized group of L-arginine 
metabolizing enzymes. It comprises nNOS (neuronal or type 1), iNOS (inducible or 
type 2), and eNOS (endothelial or type 3). The nNOS and eNOS are constitutively 
expressed in many different cell types, whereas iNOS displays induced expression and 
activity after stimulation by bacterial endotoxin or inflammatory cytokines. With the 
exception of iNOS, both nNOS and eNOS demonstrate activity that is dynamically 
regulated by Ca2+/calmodulin. Moreover, L-arginine can also play a structural role by 
promoting the dimerization of NOS, which is crucial in order to activate the enzymes 71. 
Additionally, NOS isoenzymes display distinct patterns of subcellular localization, which 
may be a consequence of the diverse regulation of NOS activity. For instance, nNOS is 
mainly associated with the rough endoplasmic reticulum and postsynaptic membranes in 
the brain and with the sarcolemma of skeletal muscle 72, whereas eNOS is associated with 
caveolae in the plasma membrane 73. In contrast to these two isoenzymes, iNOS is 
primarily cytsolic 59. 
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1.2.4. Arginase and nitric oxide synthase balance 
The NOS and ARG isoenzymes are reported to be expressed simultaneously 
under wide variety of conditions, which results in cross-reactions with consequences that 
are not simple to study. As both enzymes utilize L-arginine as a substrate, they can 
influence each other by limiting the substrate availability 39,74. The interplay between 
these enzymes can also be explained by their kinetics. The mammalian ARG display Km 
values for L-arginine that are in the 2–20 mM range, whereas the NOS Km is in the 
2-20 µM range. Nevertheless, the Vmax for ARG at physiological pH is more than 
1000-fold higher than the NOS Vmax, which in the rat liver are approximately 
1400 µmol/min per mg, and 1 µmol/min per mg, respectively. This suggests that ARG 
activity is able to limit L-arginine for NO synthesis in these cells 67,75. Thus, several 
investigations have shown that ARG limits NO production by NOS, under some 
circumstances 76-78. The converse situation has not been demonstrated yet, what is 
connected with the fact that synthesis of NO is accompanied by production of 
NG-hydroxy-L-arginine (NOHA). This intermediate of NO synthesis behaves as an 
endogenous inhibitor of ARG, therefore, it is speculated that the inhibitory effects of 
NOS on ARG activity reflect rather the inhibitory potential of NOHA 79, which leads to 
the conclusion that the interplay between both enzymatic systems is more complex than 
the fact that they use the same substrate.  
Finally, turnover of the proteins containing methylated arginine residues can also 
have an affect on NOS activity. By the action of enzymes called protein arginine 
methyltransferases (PRMT) the arginine residues incorporated into proteins can be 
methylated. Further degradation of such proteins leads to the release of monomethylated 
(NMMA), asymmetrically dimethylated (ADMA), and symmetrically dimethylated 
(SDMA) arginine. The first two of these modified L-arginine types behave as NOS 
inhibitors 80, and especially ADMA represents a risk factor for cardiovascular 
diseases 81-84. 
Thus, the balance and the crosstalk between ARG and NOS isoenzymes seem to 
be crucial under a vast number of circumstances or disease states. Nitric oxide, produced 
by the action of NOS, is a putative neurotransmitter and cytotoxic effector molecule, 
which causes vasodilatation of blood vessels. These characteristics make NOS and NO 
pivotal factors in various cardiovascular diseases, congestive heart failure, and coronary 
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artery disease. In turn, elevated expression of ARG during inflammation or infection may 
not only decrease levels of NO, but also stimulate the synthesis of proline and polyamines 
via increased production of ornithine 85. This ARG-mediated increase of polyamine and 
proline production 86 subsequently promotes cell proliferation 87 and a collagen synthesis. 
These processes play important roles in infections, chronic inflammatory diseases, and 
particularly in wound healing and fibrotic disorders.  
Thus, several studies suggest that L-arginine is a crucial player in many disease 
states, and its supplementation may have an effect on the recovery process of the 
organism 41,88-90. Moreover, the complexity of multiple metabolic pathway of L-arginine 
indicates the importance of the crosstalk between single enzymes, but also suggests that 
the imbalance between them may be critical in the development of several diseases in 
which processes including abnormal wound healing connected with cell overproliferation 
are involved. 
 
 
1.2.4.1. Functional consequences of arginase and nitric oxide synthase regulation 
It is well characterized that L-arginine metabolism is mainly determined by the 
activity of ARG and NOS isoenzymes. It is also known that these two enzymes may be 
differentially regulated within diverse cell types as well as under variety of conditions. 
For instance, activity of iNOS and both ARG isoenzymes was reported to be increased in 
mouse macrophages upon LPS exposure 91,92. In several other studies, it was 
demonstrated that wound and peritoneal macrophages convert L-arginine to citrulline and 
ornithine at comparable rates, which can indicate that both NOS and ARG pathways are 
functional 93. However, other reports demonstrated differential regulation of iNOS and 
ARG isoenzymes in RAW 264.7 macrophages and mouse peritoneal macrophages upon 
8-bromo-cAMP and Interferon-γ stimulation 68. Experiments performed on cardiac 
myocytes demonstrated that ARG2 is predominant in these cells, and can negatively 
regulate nNOS activity 76. The upregulation of ARG isoforms was also shown in disease 
processes in which NO signaling is dysregulated, for example, endothelial dysfunction of 
aging 94, hypertension 95, atherosclerosis 96, and erectile dysfunction of diabetes 97,98. 
Uncontrolled upregulation of ARG expression was also reported in the myeloid 
suppressor cells in renal cell carcinoma patients 99. The high activity of these enzymes 
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originated from tumor cells, in which the metabolism of L-arginine to ornithine is 
required to maintain rapid cell proliferation. Depletion of L-arginine may lead to the 
limited production of NO and difficulties in immune response to the disease state. In 
contrast to the negative influence of ARG overexpression on homeostasis and the 
development of several diseases, there are data pointing to protective roles of ARG in 
mouse model of colitis 100. As iNOS activity worsen the state of colitis patient, 
upregulation of ARG with its enhanced production of polyamines plays a beneficial role 
in recovery. The balance between NOS and ARG seems to be crucial also for the 
processes of wound and skin repair. Upon injury of healthy skin, the activity of ARG 
isoenzymes as well as iNOS was demonstrated to be elevated and localized in epithelial 
sites 101. Diabetes-impaired skin repair was characterized by abnormally elevated ARG 
activity in wound tissues where iNOS expression was absent leading to decreased NO 
production. These lower NO levels led to impaired re-epithelialization within the wound. 
Both enzymes were also suggested to be important in the pathophysiology of 
psoriasis 102. Overexpression of ARG1 in psoriatic skin lesions led to the limited iNOS-
mediated synthesis of NO in vivo, which was beneficial, since the high output of NO, 
a potent regulator of proliferation and differentiation, contributes the hyperproliferative 
disease state in psoriasis. 
 
 
1.2.4.2. Arginase and nitric oxide synthase regulation in lung disorders 
Different combinations of cytokines can regulate ARG and NOS in diverse ways. 
The Th1-associated cytokines INF-γ or TNF-α activate iNOS, whereas the Th2-type 
cytokines IL-4, IL-10, and IL-13 appear to induce ARG 85,103. These characteristics may 
underlie the differential regulation of these two enzymes upon inflammatory stimulation, 
included in several lung disorders. 
Studies performed on tissue biopsies from patients with asthma revealed that this 
lung disorder is characterized by chronic airway inflammation associated with lung 
remodeling. Further studies performed in a mouse asthma model demonstrated high 
induction of ARG1 and ARG2 expression during development of the disease 104. 
Arginase-1 was shown to be localized in the active inflammatory sites around airways 
and blood vessels. Macrophages appeared to be the major source of these enzymes, which 
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potentially have a role in the recovery of the tissue from inflammation and infection. 
Increased expression of ARG with concomitant suppression of NO generation led to 
airway hyperresponsiveness and increased generation of mucus and collagen, which may 
contribute to pathogenesis of asthma.  
The balance between NOS and ARG activity was also shown to be disturbed in 
cystic fibrosis (CF). Airway disease in CF is characterized by chronic inflammation, 
chronic bacterial infection, and infection-associated pulmonary exacerbations 105. Despite 
the inflammatory character of this lung disease, patients exhibit lower levels of fractional 
exhaled NO and bioactive NO in airway fluids. This decreased NO production has 
a negative influence on the defense against bacterial infections, and contributes to airway 
obstruction. The results of several studies demonstrated increased activity of ARG in 
patients with CF, which as in asthma, limits substrate for NO generation and in 
consequence leads to decrease in iNOS activity 106,107. 
These findings suggested that L-arginine depletion caused by increased ARG 
activity may play a pivotal role in the diseases connected with increased smooth muscle 
contractility. In line with this indication, experiments carried out on patients with 
pulmonary arterial hypertension (PAH) revealed significantly higher activity of ARG in 
lysates of bronchial and vascular tissue of lungs from patients with PAH as well as in 
lung endothelial cells 108. The L-ornithine originating from ARG activity contributes to 
vascular remodeling in PAH via conversion to polyamines and proline 109. 
 
 
1.2.4.3. L-Arginine metabolism in idiopathic pulmonary fibrosis 
A dysregulated ARG/NOS balance in several lung disorders, as well as the 
activity of ARG in the production of polyamines and proline that control cell proliferation 
and collagen production, respectively, suggest an important role of ARG in fibrotic 
diseases. The role of ARG in the pathogenesis of IPF remains to be fully elucidated, since 
only a low number of studies have been performed up until now in this field. One report 
indicated higher expression of pulmonary ARG1 in a mouse model of herpes virus-
induced lung fibrosis 110. Additionally, the induction of both ARG isoenzymes in 
macrophages in bleomycin-induced lung fibrosis was demonstrated 111.  
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However, no data demonstrating a functional involvement of ARG in IPF 
pathogenesis have been published thus far. It is well known that several interleukins, 
growth factors, and chemokines are involved in IPF development, however, one of them, 
transforming growth factor-beta (TGF-β) seems to play an important, if not pivotal, role 
in IPF pathogenesis. The presence of active TGF-β in the lung leads to induction of 
altered alveolar and parenchymal structures, development of honeycomb structures, 
presence of fibroblasts and myofibroblasts, enhanced matrix deposition, and collagen 
synthesis 112. Of interest are the studies demonstrating that TGF-β1-stimulated collagen 
production is dependent on proline formation. Moreover, it has been shown that TGF-β1 
stimulates polyamine and proline generation by the induction of genes regulating the 
transport and metabolism of L-arginine 56. These findings indicate a possible link 
between arginine metabolism and IPF pathogenesis, and explain the need for further 
investigation of L-arginine metabolizing enzymes.  
 
Aim of the study  20 
2. Aim of the study 
 
It is well-established that an imbalance between the L-arginine metabolic enzymes 
arginase and nitric oxide synthase, may contribute to the development of several lung 
diseases. Arginase may significantly impact collagen synthesis due to augmented 
L-proline bioavailability, endothelial dysfunction of the pulmonary vascular bed due to 
decreased NO synthesis, and increased cell proliferation induced by the enhanced 
bioavailability of polyamines. As these processes are reported to be involved in the 
pathogenesis of idiopathic pulmonary fibrosis, this project aims to functionally 
characterize L-arginine metabolic enzymes in experimental and idiopathic pulmonary 
fibrosis. In this context, the research focus was: 
 
1. Expression analysis of L-arginine metabolic enzymes in a mouse model of 
bleomycin-induced lung fibrosis. 
2. Elucidation of the role of these enzymes and their impact on cellular L-arginine 
levels. 
3. Analysis of TGF-β contribution to the regulation of L-arginine metabolic 
enzymes. 
4. Verification of these results in lung specimens from IPF patients.  
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3. Materials and Methods 
3.1. Materials 
3.1.1. Equipment 
ABI PRISM 7500 Sequence Detection System  Applied Biosystems, USA 
C57BL/6N mice      Charles River, Germany 
Cell Culture Incubator; Cytoperm2     Heraeus, Germany 
Chroma SPIN-1000 DEPC-H2O Columns   Biosciences, Clontech, USA 
Developing machine; X Omat 2000     Kodak, USA 
Electrophoresis chambers      Bio-Rad, USA 
Film cassette       Sigma-Aldrich, Germany 
Filter Tip FT: 10, 20, 100, 200, 1000    Greiner Bio-One, Germany 
Filter units 0,22 µm syringe-driven     Millipore, USA 
Fluorescence microscope; LEICA AS MDW   Leica, Germany  
Freezer -20 °C      Bosch, Germany 
Freezer -40 °C      Kryotec, Germany 
Freezer -80 °C      Heraeus, Germany 
Fridge +4 °C       Bosch, Germany 
Fusion A153601 Reader     Packard Bioscience, Germany  
Gel blotting paper 70 × 100 mm     Bioscience, Germany 
Glass bottles: 250, 500, 1000 ml     Fischer, Germany 
GS-800TM Calibrated Densitometer   Bio-Rad, USA 
HPLC system:  
ASI-100 auto sampler    Dionex, USA 
P680 gradient pump    Dionex, USA 
RF-2000 fluorescence detector  Dionex, USA 
Data acquisition system Chromeleon 6.60, Dionex, USA 
Light microscope Olympus BX51     Olympus, Germany 
µBondapak™ C18 guard column    Waters, USA 
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Mini spin centrifuge       Eppendorf, Germany 
Multifuge centrifuge, 3 s-R      Heraeus, Germany 
Oasis MCX solid-phase extraction cartridges   Waters, USA 
PCR-thermocycler       MJ Research, USA 
Pipetboy        Eppendorf, Germany 
Pipetmans: P10, P20, P100, P200, P1000    Gilson, France 
Power Supply; Power PAC 300     Bio-Rad, USA 
Petri dish with vents       Greiner Bio-One, Germany 
Pipette tip: 200, 1000 µl,     Sarstedt, Germany 
Pipette tip 10 µl       Gilson, USA 
Quantity One software     Bio-Rad, USA 
Radiographic film X-Omat LS     Sigma-Aldrich, Germany 
Serological pipette: 5, 10, 25, 50 ml    Falcon, USA 
SunFire™ C18 column     Waters, USA 
Test tubes: 15, 50 ml       Greiner Bio-One, Germany 
Tissue culture chamber slides     BD Falcon, USA 
Tissue culture dish 100 mm      Greiner Bio-One, Germany 
Tissue culture flask 250 ml      Greiner Bio-One, Germany 
Tissue culture plates: 6, 48 well    Greiner Bio-One, Germany 
Trans blot transfer medium (0,2 µm)    Bio-Rad, USA 
Western Blot Chambers:  
Mini Trans-Blot     Bio-Rad, USA 
Mini-Protean 3 Cell     Bio-Rad, USA 
Vortex machine       Eppendorf, Germany 
Vacuum centrifuge      Eppendorf, Germany 
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3.1.2. Reagents 
Acetonitrile       Roth, Germany 
Acrylamide solution, Rotiphorese Gel 30   Roth, Germany 
Agarose        Invitrogen, UK 
Albumine, bovine serum     Sigma-Aldrich, Germany 
Ammonium persulphate     Promega, Germany 
Ammonium sulphate       Sigma-Aldrich, Germany  
β-glycerophosphate      Sigma-Aldrich, Germany 
β-mercaptoethanol       Sigma-Aldrich, Germany 
Bleomycin sulphate      Almirall Prodesfarme, Spain 
Bromophenol blue       Sigma-Aldrich, Germany 
Calcium chloride       Sigma-Aldrich, Germany 
CompleteTM Protease inhibitor    Roche, Germany 
D-(+)-Glucose       Sigma-Aldrich, Germany 
D-MEM medium       Gibco BRL, Germany 
D-MEM medium      Sigma-Aldrich, Germany 
Dimethyl sulfoxide      Sigma-Aldrich, Germany 
DNA Ladder (100 bp, 1kb)     Promega, USA 
Ethylendinitrilo-N, N, N´, N´, -tetra-acetic-acid (EDTA)  Promega, USA 
Ethylene glycol-bis (2-amino-ethylether)-N,N,N’,N’ 
-tetraacetic-acid (EGTA)     Sigma-Aldrich, Germany 
Dulbecco’s phosphate buffered saline 10× PAA Laboratories, Austria 
Dulbecco’s phosphate buffered saline 1× PAA Laboratories, Austria 
Ethanol absolute       Riedel-de Haën, Germany 
ECL Plus Western Blotting Detection System  Amersham Biosciences, UK 
Ethidium bromide      Roth, Germany 
Fetal calf serum (FCS)     Gibco BRL, Germany 
Glycine       Roth, Germany 
GoTaq® Flexi DNA polymerase    Promega, USA 
Hydrochloric acid       Sigma-Aldrich, Germany 
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2-(-4-2-hydroxyethyl)-piperazinyl-1-ethansulfonate  
(HEPES)       Sigma-Aldrich, Germany 
Igepal CA-630       Sigma-Aldrich, Germany 
ImProm-IITM Reverse Transcriptase    Promega, USA 
L-arginine       Sigma-Aldrich, Germany 
LipofectamineTM 2000     Invitrogene, UK 
Luciferase Assay Reagent 10-Pack    Promega, USA 
Luciferase Cell Culture Lysis 5× Reagent   Promega, USA 
Magnesium chloride       Sigma-Aldrich, Germany 
Magnesium sulfate       Sigma-Aldrich, Germany 
Methanol        Fluka, Germany 
NG-hydroxy-L-arginine, monoacetate salt (NOHA)  Calbiochem, Germany 
N,N,N',N'-tetramethyl-ethane-1,2-diamine (TEMED) Bio-Rad, USA 
Oligo(dT)15 Primer      Promega, USA 
Opti-MEM medium       Gibco BRL, Germany 
Ortho-phthaldialdehyde (OPA) Grom-chromatography, 
Germany 
PCR Nucleotide Mix      Promega, USA 
Penicillin-streptomycin     PAA Laboratories, Austria 
Potassium acetate       Sigma-Aldrich, Germany 
Potassium borate  Grom-chromatography, 
Germany 
Potassium chloride       Merck, Germany 
Potassium phosphate       Sigma-Aldrich, Germany 
Precision Plus ProteinTM Standards     Bio-Rad, USA 
2-Propanol        Merck, Germany 
QIAprep Spin Miniprep Kit     Qiagen, Germany 
QuantiChrom™ Arginase Assay Kit    BioAssay Systems, USA 
Quick StartTM Bradford Dye Reagent   Bio-Rad, USA 
RNAsin inhibitor      Promega, Germany 
RNeasy Midi Kit      Qiagen, Germany 
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Roti®-Quick-Kit       Roth, Germany 
SircolTM, Soluble Collagen Assay    Biocolor, UK 
Sodium acetate       Sigma-Aldrich, Germany 
Sodium chloride       Merck, Germany 
Sodium dodecyl sulfate (SDS)    Promega, USA 
Sodium ortho vanadate     Sigma-Aldrich, Germany 
Sodium phosphate       Sigma-Aldrich, Germany 
Sodium sulfate       Merck, Germany 
SuperSignal® West Pico Chemiluminescent Substrate Pierce, USA 
SYBER® Green PCR Kit     Qiagen, Germany 
Transforming growth factor β1 (TGF-β1)   R&D Systems, USA 
Tween 20        Sigma-Aldrich, Germany 
Tris         Roth, Germany 
Triton X-100        Promega, USA 
Trypsin/EDTA       Gibco BRL, Germany 
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3.1.3. Mammalian cells 
3.1.3.1. Cell lines 
NIH-3T3 (Swiss mouse embryo), fibroblasts, DSMZ, Germany 
 
3.1.3.2. Primary cells  
Mouse primary lung fibroblasts were isolated from bleomycin-treated and saline-
treated animals. Human primary lung fibroblasts were isolated from tissues obtained from 
healthy transplant donors, as described in 3.2.12.2.  
 
3.1.4. Animal model of pulmonary fibrosis 
3.1.4.1. Bleomycin-induced lung fibrosis in mice 
Bleomycin is an effective antineoplastic drug, nevertheless its repeated systemic 
administration may result in lung inflammation that can progress to fibrosis. Because 
bleomycin-induced lung fibrosis is easily reproduced in many different mammalian 
species, an experimental model using this drug was adopted with a goal of investigating 
the cellular and molecular basis of interstitial lung fibrosis.  
All animal studies in the project were performed according to the guidelines of the 
University of Giessen and approved by the local authorities (Regierungsprasidium 
Giessen, no. II25.3–19c20–15; GI20/10-Nr.22/2000). Specific pathogen-free female 
C57BL/6N mice weighing 18-20 g (supplied by Charles River, Sulzfeld, Germany), were 
used. Bleomycin was dissolved in 0,9 % PBS and administered as a single dose of 
0,08 mg in 200 µl saline solution per animal via microsprayer application on day 0. 
Control animals received only PBS. Pathological changes were already observed seven 
days after treatment. Mice were sacrificed for analysis at 3, 5, 7, 14, 21 days after 
exposure to bleomycin, and animal lungs were collected and processed for embedding 
and sectioning, reserved for primary fibroblasts isolation, or immediately snap-frozen in 
liquid nitrogen. 
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3.2. Methods 
3.2.1. RNA isolation 
Isolation of RNA from lung tissue and cultured cells material was performed 
according to the manufacturer’s instructions provided with a RNeasy Midi Kit and 
Roti®-Quick-Kit, respectively. 
 
3.2.2. Reverse transcription reaction 
Reverse transcription polymerase chain reaction (RT-PCR) is an enzymatic 
process performed by an enzyme called reverse transcriptase. This enzyme synthesizes 
complementary DNA (cDNA) using RNA as a template.  
In order to perform RT-PCR, 500 ng of mouse or human total RNA was added to 
1 µl of oligo-(dT)15 (100 µg/ml). The reaction mixture was heated to 70 °C for 5 min, 
chilled on ice, and the following RT reagents were added: 
 
RT reaction component Volume Final concentration 
5× RT Buffer (free MgCl2) 4 µl 1× 
25 mM MgCl2 4,8 µl 6 mM 
10 mM dNTP mix 1 µl 0,5 mM 
RNAsin inhibitor (1 U/µl)  1 µl 1 U 
Reverse transcriptase  
(1 U/µl) 1 µl 1 U 
H2O (RNase free) to 20 µl not applicable 
 
 
To synthesize cDNA, the reaction mixture was incubated at 25 °C for 5 min and at 42 °C 
for 1 h. Synthesized cDNA was either stored at -20 °C or used for other experiments 
directly. 
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3.2.3. Polymerase chain reaction 
The polymerase chain reaction (PCR) is an enzymatic technique that facilitates the 
production of millions of copies of specific DNA. The amplification of cDNA, previously 
reverse-transcribed from RNA, is carried out by an enzyme called DNA polymerase. 
Principally, each PCR cycle consists of three steps: 
 
Denaturation - separation of double-stranded DNA to single strands. 
Annealing  - primers binding to the appropriate sequence of single DNA 
strands. 
Elongation - synthesis of a new DNA strand by DNA polymerase. 
 
3.2.3.1. Semi-quantitative polymerase chain reaction 
Semi-quantitative PCR reaction in principal proceeds as described in 3.2.3. 
Amplification of cDNA was performed according to the manufacturer’s instructions 
provided with the GoTaq® Flex DNA Polymerase. The PCR reaction mix was prepared 
as follows: 
 
PCR reaction component Volume Final concentration 
5× PCR Buffer (free MgCl2) 10 µl 1× 
25 mM MgCl2 5  µl 2,5 mM 
10 mM dNTP mix 1 µl 0,2 mM 
10 µM forward primer* 1 µl 0,2 µM 
10 µM reverse primer* 1 µl 0,2 µM 
Taq DNA Polymerase (5 U/µl) 0,25 µl 1,25 U 
cDNA template 1 µl not applicable 
H2O (autoclaved) to 50 µl not applicable 
 
* All primer sequences are listed in Table 6.1.2. 
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The PCR reaction components were mixed on ice and transferred to a PCR 
machine. To perform effective amplification of cDNA, the following program was 
performed: 
Step Timee Temperature 
Denaturation 1 min 94 °C 
Annealing 1 min 57-60 °C* 
Elongation 30 s 72 °C 
 
* Annealing temperatures varied depending on the primers used in the experiment. 
The steps were repeated in 22-28 cycles depending on the amplified sequence. Amplicons 
were immediately separated by the agarose gel electrophoresis and visualized by staining 
with ethidium bromide. 
 
3.2.3.2. Real-time polymerase chain reaction 
Quantitative Real Time PCR is used to simultaneously quantify and amplify 
specific sequence of DNA. The procedure follows the PCR strategy but after each 
amplification round, the DNA is quantified. Quantification is performed by means of 
fluorescent dye – SYBR® Green I – which directly binds to double-stranded DNA. The 
bound dye generates a signal that is proportional to the DNA concentration.  
Reactions were performed according to the manufacturer’s instructions provided 
with a SYBER® Green PCR Kit. PCR reaction mix was prepared as follows: 
 
PCR reaction component Volume Final concentration 
Platinum® Syber® Green 
qPCR SuperMix-UDG 13 µl 1× 
50 mM MgCl2 1  µl 2 mM 
10 µM forward primer* 0,5 µl 0,2 µM 
10 µM reverse primer* 0,5 µl 0,2 µM 
cDNA template 1 µl not applicable 
H2O (autoclaved) to 25 µl not applicable 
Materials and Methods  30 
 
* All primers sequences are listed in Table 6.1.1. 
The amplification and quantification of cDNA was carried out by means of following 
program: 
 
Step Timee Temperature 
Denaturation 5 s 95 °C 
Annealing 5 s 59-60 °C* 
Elongation 30 s 72 °C 
 
*Annealing temperatures varied depending on the primers used in the experiment. 
The steps were repeated in 45 cycles. 
A ubiquitously- and equally-expressed gene that is free of pseudogenes was used as the 
reference gene in all quantitative real time PCR reactions. The relative transcript 
abundance of a gene was presented as ∆Ct values (∆Ct = Ctreference – Cttarget). Relative 
changes in transcript levels compared to controls were displayed as ∆∆Ct values 
(∆∆Ct = ∆Cttreated – ∆Ctcontrol). All ∆∆Ct values corresponded approximately to the binary 
logarithm of the fold change. 
 
3.2.4. DNA agarose gel electrophoresis 
Agarose gel electrophoresis was performed in order to separate and analyze DNA 
products obtained by PCR. Percentage of the gels varied 1–2,5 % depending on the size 
of the DNA amplicon. Agarose was mixed with 1× TAE buffer and 0,5 µg/ml ethidium 
bormide – a DNA intercalating dye – that enables visualization of the DNA fragments 
under ultraviolet light. The DNA samples were mixed with 6× DNA loading buffer and 
loaded onto the gel. Electrophoresis was performed at 100 V/cm in 1× TAE buffer. 
 
1× TAE:  
40 mM Tris-acetate, pH = 8,0 
1 mM EDTA, pH = 8,0 
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6× DNA loading buffer: 
0,025 % (w/v) bromophenol blue 
40 % (w/v) sucrose 
 
3.2.5. Protein isolation 
Proteins were extracted either from total lung tissue or mammalian cells. 
Depending on the biological material, two different extraction methods were performed. 
 
3.2.5.1. Protein isolation from tissues 
Lung tissue preserved in liquid nitrogen was homogenized by addition of ice-cold 
tissue lysis buffer. Tissue lysate was then passed 5–8 times through a 0,9 mm gauge 
needle fitted to a Rnase-free syringe. Homogenized tissue was then incubated for 30 min 
on ice and centrifuged 15 000 × g for 15 min at 4 °C. Resulting supernatant was used as 
a tissue extract and stored at -20 °C for further experiments.  
 
Tissue lysis buffer: 
20 mM Tris-HCl, pH = 7,5 
150 mM NaCl 
1 mM EDTA 
1 mM EGTA 
1 % Trition X-100 
2,5 mM Na3PO4 
1 mM β-glycerophosphate 
1 mM Na3VO4, phosphates inhibitor – added immediately prior homogenization 
Complete™, protease inhibitor mix – added immediately prior homogenization 
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3.2.5.2. Protein isolation from cells 
Cells were harvested at indicated time points by scraping in the cell lysis buffer 
with a rubber policeman. Collected cells were passed 5–8 times through a 0,9 mm gauge 
needle until a homogenous lysate was obtained. Lysates were then incubated for 30 min 
on ice and centrifuged 15 000 × g for 15 min at 4 °C. Resulting supernatants were used as 
cell extracts and stored at -20 °C for further experiments.  
 
Cell lysis buffer: 
20 mM Tris-HCl, pH = 7,5 
150 mM NaCl 
1 mM EDTA 
1 mM EGTA 
0,5 % Igepal CA-630 
1 mM Na3VO4, phosphates inhibitor – added immediately prior homogenization 
Complete™ , protease inhibitor mix – added immediately prior homogenization 
 
3.2.5.3. Protein quantification 
Protein concentrations in tissue and cell extracts were spectrophotometrically 
determined using Quick Start™ Bradford Dye Reagent and a Fusion A153601 Reader 
according to the manufacturer’s instructions. The protein assay is based on the color 
change of Coomassie Brilliant Blue G-250 dye in response to various protein 
concentrations. The dye binds primarily to basic and aromatic amino acids residues. Ten 
microliters of sample was mixed with 200 µl of Bradford Dye Reagent and transferred to 
a 96-well plate. Six dilutions of protein standard, bovine serum albumin, 0,05–0,5 µg/µl 
were prepared and mixed with Bradford Dye Reagent in the same ratio as the sample of 
unknown concentration. Reaction mixtures were incubated for 15 min at room 
temperature. The absorbance of the samples was measured at 570 nm. The unknown 
amount of protein in the sample was determined by interpolation, reading the 
concentration of protein on the standard curve that corresponded to its absorbance. 
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3.2.6. SDS polyarcrylamide gel electrophoresis 
Protein extracts were separated by means of SDS polyacrylamide gel 
electrophoresis (SDS-PAGE). Before loading onto the gel, 30 µg of protein was 
combined with 10× SDS-loading buffer, and denaturated by heating for 5 min at 100 °C. 
Separation of proteins was performed in the gel consisting of 5 % stacking gel and 10 % 
resolving gel. Electrophoresis was carried out in SDS-running buffer at 120 V.  
 
10× SDS-loading buffer: 
625 mM Tris-HCl, pH = 6,8 
50 % (v/v) glycerol 
20 % (w/v) SDS 
9 % (v/v) β-mercaptoethanol 
0,3 % (w/v) bromophenol blue 
 
Stacking gel:  
5 % acrylamide:bisacrylamide 
125 mM Tris-HCl, pH = 6,8 
0,1 % (w/v) SDS 
0,1 % (w/v) APS 
0,1 % (v/v) TEMED 
 
Resolving gel: 
10 % acrylamide:bisacrylamide 
375 mM Tris-HCl, pH = 8,8 
0,1 % (w/v) SDS 
0,1 % (w/v) APS 
0,1 % (v/v) TEMED 
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SDS-running buffer: 
25 mM Tris  
250 mM glycine 
0,1 % (w/v) SDS 
 
3.2.7. Immunoblotting 
Immunoblotting was performed in order to visualize and detect specific proteins 
separated previously by means of SDS-PAGE.  
 
3.2.7.1. Protein blotting 
Proteins separated by SDS-PAGE were transferred to 0,25 µm pure nitrocellulose 
membrane or ployvinylidene difluoride (PVDF) membrane depending on the experiment. 
Activation of the PVDF membrane was carried out in 100 % methanol directly prior to 
protein blotting. Transfer was performed in transfer buffer at 120 V for 1 h.  
 
Transfer buffer: 
25 mM Tris 
192 mM glycine 
20% (v/v) methanol  
 
3.2.7.2. Protein detection 
Membranes were blocked in blocking solution for 1 h at room temperature. The 
PVDF membranes were dried prior to blocking and soaked with 100% methanol. After 
blocking, membranes were incubated with the appropriate primary antibodies either for 
1 h at room temperature or overnight at 4 °C *. Afterwards membranes were washed 
three times for 10 min with 1× PBST buffer, incubated with horse radish peroxidase-
labeled secondary antibody for 1 h at room temperature, and then washed five times for 
10 min with 1× PBST. Specific bands were visualized by chemiluminescence using an 
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Enhanced Chemiluminescence Immunoblotting system. In order to re-probe membranes 
with another antibody, membranes were stripped with stripping buffer for 15 min at 
52 °C and subsequent protein detection was performed as described above.  
 
Blocking solution: 
5 % (w/v) non-fat dry milk 
1× PBS 
0,1 % (v/v) Tween-20 
 
1× PBST: 
1× PBS 
0,1 % (v/v) Tween-20 
 
Stripping buffer: 
62,5 mM Tris-HCl, pH = 6,8 
2 % (w/v) SDS 
100 mM β-mercaptoethanol  
 
* Primary antibody concentrations varied depending on the antibodies used in the 
experiment, and are presented in Tables 6.2.1. and 6.2.2. 
 
3.2.8. Densitometry 
Densitometric analysis of autoradiography was performed using a GS-800TM 
Calibrated Densitometer and the 1-D analysis software Quantity One. Protein expression 
was normalized to β-actin levels detected by an anti-β-actin antibody. 
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3.2.9. Immunohistochemistry 
In order to localize and detect expression of indicated proteins in the lung tissue, 
immunochistochemical analysis was performed using a Histostain-SP Kit. Whole lung 
sections were deparaffinized in xylene three times for 10 min, and rehydrated in 100 % 
ethanol twice for 5 min, 95 % ethanol twice for 5 min, 70 % ethanol twice for 5 min, and 
1× PBS twice for 5 min. Antigen retrieval was performed by incubation of the slides in 
1× citrate buffer for 20 min at 100 °C, followed by cooling the slides for next 10 min. 
Endogenous peroxidase activity was quenched by incubating the sections with 3 % (v/v) 
H2O2 for 10 min. Sections were blocked with blocking solution provided in the kit for 
10 min at room temperature, followed by incubation with the primary antibody overnight 
at 4 °C *. Afterwards, sections were washed twice with 1× PBS for 5 min, and incubated 
with biotinylated secondary antibodies for 10 min, followed by the streptavidin-
conjugated enzyme for 10 min, and chromogenic substrate for 10 min. Slides were 
developed for 5 min with diaminobenzidine (DAB) and counterstained with Mayers 
hematoxylin. Sections were mounted using mounting medium and examined for staining 
using an Olympus BX51 microscope. 
 
* Primary antibody concentrations varied depending on the antibodies used in the 
experiment, and are presented in Tables 6.2.1. and 6.2.2. 
 
3.2.10. Immunocytochemistry 
Immunocytochemistry was performed to visualize the localization of particular 
proteins inside the cells. Cells were seeded in 8-well chamber slides. After 24 h, culture 
medium was removed and cells were washed twice for 5 min with ice-cold 1× PBS. Cells 
were fixed in 100 % methanol for 5 min at -20 °C, washed twice for 5 min with 1× PBS 
and then incubated in blocking solution for 1 h at room temperature. Afterwards, cells 
were incubated with the appropriate primary antibody overnight at 4 °C *, then washed 
3 times for 5 min with 1× PBS. Subsequently, incubation with fluorescein-5-
isothiocyanate -labeled secondary antibodies (1:200 dilution) was performed for 1 h at 
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room temperature. After five washing rounds for 5 min each, performed with 1× PBS, 
chamber slides were covered with mounting medium containing 4´,6-diamidino-2-
phenylindole (1:1000 dilution) to visualize the nucleus of the cells. The localization of 
the proteins was analyzed by means of fluorescent microscopy.  
 
Blocking solution: 
5 % (v/v) FCS 
1× PBS 
 
* Primary antibody concentrations varied depending on the antibodies used in the 
experiment, and are presented in Tables 6.2.1. and 6.2.2. 
 
3.2.11. Amino acid analysis 
3.2.11.1. Isolation of basic amino acids 
All procedures were performed as previously described 113. Tissue extracts were 
subjected to crude fractionation on Oasis MCX solid–phase extraction cartridges (30 mg, 
1 ml). One-hundred microliters of each sample was then adjusted to a final volume of 
1 ml with PBS. All conditioning, washing, and elution steps were performed on 
a vacuum–manifold with a capacity for 20 columns at a flow rate of 0,5 ml/min. The SPE 
cartridges were conditioned with 2 ml of methanol/water/ammonia (50:45:5, v/v/v), 
followed by 2 ml PBS prior to sample application. Samples were passed through SPE 
cartridges and contaminating components were removed with 2 ml of 0,1 M HCl, 
followed by 2 ml methanol. Basic compounds were eluted with 1 ml of 
methanol/water/ammonia (50:45:5, v/v/v). Samples were dried in a vacuum centrifuge 
and used immediately or stored at -20 °C until analysis. Eluates were redissolved in 
230 µl of distilled water and centrifuged at 14 000 × g for 2 min to remove particulates 
prior to derivatization for high performance liquid chromatography. 
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3.2.11.2. Derivatization and chromatographic separation 
All procedures were performed as previously described 114. The ortho-
phthaldialdehyde reagent (OPA) was freshly prepared in potassium borate buffer, 
according to the manufacturer’s instructions. Thirty microliters of each sample was 
combined with 62,5 µl of OPA, immediately transferred to the auto sampler, and injected 
exactly after 2 min. Quantification of amino acids was performed on a HPLC system 
consisting of an ASI-100 auto sampler, a model P680 gradient pump, a model RF-2000 
fluorescence detector, and a data acquisition system Chromeleon 6.60. Separation was 
performed according to a method previously described 113. Fluorescent amino acid 
derivatives were separated on a SunFireTM C18 column (4,6 × 150 mm; 3,5 µm particle 
size; 100 Å pore size) with a µBondapakTM C18 guard column at 30 °C and a flow rate 
of 1,1 ml/min. After injecting 125 µl of the sample, separation was performed under 
isocratic conditions with 8,8 % (v/v) acetonitrile in 25 mM potassium phosphate buffer 
(pH = 6,8) as solvent. The isocratic conditions were maintained for 12 min. In order to 
elute strongly bound compounds, the column was flushed with acetonitrile/water (50:50, 
v/v) for 15 min and reequilibrated under isocratic conditions for 25 min prior to the next 
injection. Fluorescent derivatives were detected at excitation and emission wavelengths 
of 330 and 450 nm, respectively. Calibration was performed by external calibration with 
L-arginine standard. 
 
3.2.12. Culture of mammalian cells 
3.2.12.1. Cell culture condition 
The mouse fibroblast NIH-3T3 cell line and primary mouse and human lung 
fibroblasts were grown in plate culture dishes in D-MEM medium containing 10 % (v/v) 
fetal calf serum (FCS) at 37 °C, 5 % CO2 and 95–100 % humidity. Cells were passaged 
after achieving 80-90 % confluence. Cells were washed with 1× PBS and then incubated 
with 3 ml trypsin/EDTA solution for 2–3 min in order to detach the cells. Seven 
milliliters of D-MEM containing FCS was added to cells to further block the enzymatic 
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reaction. The cell suspension was transferred to the new culture dishes in dilution 1:5 
or 1:10.  
PBS (phosphate-buffered saline): 
0,08 % (w/v) NaCl 
0,02 % (w/v) KCl 
0,115 % (w/v) Na2HPO4 · 2H2O 
0,02 % (w/v) KH2PO4 · 2H2O 
pH = 7,4 adjusted with NaOH; sterilized for 20 min at 121 °C, 15 psi 
 
Trypsin/EDTA solution: 
0,25 % (w/v) trypsin 
1,23 g/l EDTA 
 
3.2.12.2. Isolation of primary lung fibroblasts 
Mouse lung primary fibroblasts were isolated from bleomycin- and saline-treated 
animals, while human lung primary fibroblasts were derived from healthy transplant 
donors. In order to isolate primary lung fibroblasts, human and mouse tissues were 
processed in the same way. Lungs were perfused free of blood, and individual lung lobes 
were removed to a petri dish. Using sterile technique, lung lobes were finely minced with 
scissors, and lung mince was cultured for 10–14 days in D-MEM containing 10 % FCS 
and antibiotics (100 U/ml penicillin, 100 µg/ml streptomycin). After 10 days, fibroblasts 
had grown out from the tissue and were passaged by standard trypsinization. To insure 
the purity of the culture, cells were morphologically characterized by light microscopy, 
additionally specific staining for α-smooth muscle actin and vimentin was performed. For 
experiments described here, cells from early passages were used. Cells were plated at 
30 000 cells/cm2 either in 6-well plates or in 100-mm plates, depending on the 
experiment. 
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3.2.12.3. Transient transfection using lipofectamine 
In principal, transient transfection consists on transfer of foreign DNA into the 
eukaryotic cell. As introduced DNA is not inserted into the genome, it is lost by the cell 
in the later stages of the cell cycle.  
The NIH-3T3 cells were seeded onto culture plates dishes at a density 
20 000 cells/cm2, and were cultured in D-MEM containing 10 % FCS for 24 h to achieve 
80–90 % confluency. The transfection was performed using Lipofectamine™ 2000 
transfection reagent. Lipofectamine (2,5 µl per 1 µg of transfected DNA) was mixed with 
Opti-MEM medium. After 5 min incubation at room temperature the appropriate amount 
of DNA was added to the mixture. In order to let DNA and lipofectamine create 
complexes, incubation for a further 20 min at room temperature was performed. 
Metabolized medium was aspirated from the cells, and the cells were covered with 100 µl 
of transfection mixture. After 4–6 h, the transfection mixture was removed and starvation 
medium consisting of D-MEM containing 0,1 % FCS was added to the cells. 
 
3.2.13. Luciferase assay 
An appropriate amount of NIH-3T3 cells was plated in a 48-well plate and the 
transfection procedure was conducted as described above. Luciferase reporter plasmids 
pCAGA12-luc, or pGL3-control, at 0,2 µg/well, were used for transfection with 
lipofectamine. Twenty-four hours after transfection, cells were stimulated with TGF-β1 
(2 ng/ml) alone or TGF-β1 (2 ng/ml) in combination with the ARG inhibitor NOHA, at 
the following concentrations: 20 µM, 100 µM and 500 µM. Twenty-four hours after the 
stimulation, medium was aspirated and 100 µl luciferase lysis buffer was added to each 
well. The cells were incubated with shaking for 30–40 min at room temperature. 
Subsequently, 40 µl of cell lysate was combined with 50 µl of luciferase assay reagent 
and transferred into a 96-well plate. The luminescence of the sample was analyzed in 
a Fusion A153601 Reader. 
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3.2.14. Sircol collagen assay 
Total collagen content in cell lysates was determined using the Sircol Collagen 
Assay Kit according to the manufacturer’s instructions. This is a quantitative dye–binding 
method designed to analyze the amount of collagen produced in mammalian tissues or 
cells during in vitro culture. The dye reagent contains the Sirius Red anion with sulphonic 
acid side chain groups, which react with the side chain groups of the basic amino acids 
present in collagen.  
Equal amounts of cell lysates containing 50 µg of protein were added to 1 ml of 
Sircol dye reagent followed by 30 min of mixing at room temperature. After 
centrifugation at 10 000 × g for 10 min, the supernatant was carefully removed and 1 ml 
of alkali reagent was added, and the pellet was dissolved by vortexing. Samples and 
collagen standards were analyzed at 540 nm in a Fusion A153601 Reader. Collagen 
concentrations were calculated using standard curve with acid–soluble type I collagen. 
 
3.2.15. Arginase activity assay 
Arginase activity in human lung homogenates was monitored using 
QuantiChrom™ Arginase Assay Kit according to the manufacturer’s instructions. 
The method utilizes a chromogen that forms a colored complex specifically with urea 
produced in the arginase reaction.  
Equal amounts of lung tissue extracts containing 50 µg of proteins were combined 
with 10 µl of 5× substrate buffer and the reaction mixture was incubated for 2 h at 37 °C. 
Subsequently, 200 µl of urea reagent was added to each reaction mixture, followed by 
incubation for 15 min at room temperature. Samples and urea standard were analyzed at 
520 nm in the Fusion A153601 Reader. Arginase activity, displayed in units per liter of 
sample, was calculated from the following formula: 
 
Activity = [(ODsample–ODblank):(ODstandard–ODwater)]×[Urea standard]×50×103:(40×t) 
Urea standard  - 1 mM 
t (reaction time) - 120 min 
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4. Results 
4.1. Analysis of L-arginine metabolism during bleomycin-
induced lung fibrosis 
4.1.1. Expression analysis of L-arginine transporters 
To investigate potential changes in the levels of L-arginine transporters during the 
development of lung fibrosis, mRNA expression of solute carriers family (SLC) in the 
mouse lung fibrosis model was analyzed. The mRNA was isolated from lung 
homogenates of mice subjected to bleomycin treatment for 7, 14 and 21 days, whereas 
animals treated with saline served as controls. The mRNA levels of transporters were 
determined by semi-quantitative RT-PCR (Figure 4.1.). No significant changes in the 
expression were observed during the development of lung fibrosis in the bleomycin 
mouse model. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Expression analysis of SLC during bleomycin-induced lung fibrosis. 
Expression levels of mRNA from control and bleomycin-treated mice for 7, 14 and 21 
days assessed by semi-quantitative PCR. GAPDH served as a control gene. Gels are 
representative for three independent experiments. 
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4.1.2. Analysis of protein arginine methyltransferase expression 
Protein arginine methyltransferases (PRMT) methylate L-arginine residues in 
proteins resulting in the generation of mono- and dimethylated forms of L-arginine. 
As previously mentioned, asymmetrically dimethylated (ADMA) and monomethylated 
(NMMA) L-arginine analogs behave as NOS inhibitors. In order to assess the potential 
role of PRMT isoenzymes in the pathogenesis of lung fibrosis, their expression levels 
were investigated during bleomycin-induced lung fibrosis. Both mRNA and proteins 
were isolated from mice treated with bleomycin for 7, 14 and 21 days. The analysis of 
expression on the mRNA level was performed by means of semi-quantitative RT-PCR 
(Figure 4.2.) and the results were verified by the analysis of protein levels by 
immunoblotting (Figure 4.3.). Both methods did not reveal significant changes in PRMT 
expression levels during bleomycin-induced lung fibrosis. Interestingly, PRMT5 protein 
levels were decreased three weeks after drug administration, which is during the period of 
animal recovery. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. Analysis of PRMT mRNA expression during bleomycin-induced lung 
fibrosis.  
The mRNA levels of control and bleomycin-treated mice for 7, 14 and 21 days assessed 
by semi-quantitative RT-PCR. The GAPDH gene served as a control gene. Gels are 
representative for three independent experiments. 
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Figure 4.3. Analysis of PRMT protein expression during bleomycin-induced lung 
fibrosis. 
(A) Protein expression levels of control and bleomycin-treated mice for 7, 14 and 21 days 
assessed by IB. β-actin served as a protein loading control. (B) The results obtained by IB 
were densitometrically analyzed (n=3, * p< 0,05), statistical analysis included two-tailed 
t-test.  
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4.1.3. Analysis of L-arginine catabolic enzymes expression 
In order to further study L-arginine metabolism in the mouse lung fibrosis model, 
semi-quantitative RT-PCR was performed to examine the mRNA levels of L-arginine 
catabolic enzymes. The expression of the following enzymes was analyzed: ARG1, 
ARG2, eNOS, iNOS, OAT, ODC. Three of the enzymes: eNOS, OAT, ODC did not 
exhibit any expression changes during bleomycin-induced lung fibrosis. In contrast, 
significant expression differences were observed for ARG1 and ARG2, and to a lesser 
extent, for iNOS (Figure 4.4.). While the expression of ARG1 and ARG2 was 
significantly increased seven days after bleomycin administration, iNOS expression 
gradually increased up to 21 days after treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4. Expression of L-arginine catabolic enzymes during bleomycin-induced 
lung fibrosis. 
Expression levels of mRNA from control and bleomycin-treated mice for 7, 14 and 21 
days assessed by semi-quantitative RT-PCR. The GAPDH gene served as a control gene. 
Gels are representative for three independent experiments. 
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4.1.4. Expression of arginase-1, -2 during development of lung fibrosis 
The mRNA expression of ARG1 and ARG2 in lung tissue was found to be 
enhanced at early stages (7 days) of bleomycin-induced lung fibrosis. To further verify 
the expression of ARG1 and ARG2 in lung tissue and their involvement in the process of 
fibrogenesis, expression analysis of both enzymes was performed in animals treated with 
bleomycin for 3, 5, 7, 14, 21 days using quantitative RT-PCR (Figure 4.5.). Results 
obtained demonstrated that both enzymes exhibited increased expression five days after 
bleomycin administration, reaching the highest expression seven days after bleomycin 
treatment. In detail, ARG1 exhibited a 5,7 fold induction at day 7, whereas ARG2 
exhibited only 1,5 fold induction. The expression of both ARG remained elevated until 
21 days after treatment. 
Additionally, analysis of ARG protein levels was performed by immunoblotting 
(Figure 4.6.). Interestingly, ARG1 was undetectable in the control mouse lungs. In line 
with the mRNA expression, protein levels of both enzymes revealed the highest increase 
seven days after bleomycin treatment compared to control animals, where ARG1 again 
displayed a higher fold induction than did ARG2. Also on the protein level, both enzymes 
demonstrated elevated expression until 21 days after bleomycin administration.  
 
 
 
 
 
 
 
 
 
Figure 4.5. ARG mRNA expression during bleomycin-induced lung fibrosis. 
The mRNA expression levels of control and bleomycin-treated mice for 3, 5, 7, 14 and 21 
days assessed by qRT-PCR. The PBGD gene served as a control gene, (n=3, * p< 0,05), 
statistical analysis included two-tailed t-test.  
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Figure 4.6. ARG protein expression during bleomycin-induced lung fibrosis. 
(A) Protein expression levels of control and bleomycin-treated mice for 3, 5, 7, 14 and 21 
days assessed by IB. β-actin served as a protein loading control. (B) The results obtained 
by IB were densitometrically analyzed (n=3, * p< 0,05), statistical analysis included 
two-tailed t-test.  
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4.1.5. Levels of free L-arginine during lung fibrosis 
In order to investigate whether the dramatic increase in ARG isoenzymes levels in 
the mouse lung after bleomycin treatment resulted in altered free lung L-arginine levels, 
the L-arginine concentration was determined by amino acid analysis. Free cellular 
L-arginine was measured in lung tissue homogenates, derived from control and 
bleomycin-treated mice (Figure 4.7.). Results indicated decreased L-arginine levels in the 
lung when mice were subjected to bleomycin treatment. This decrease was most evident 
seven days after bleomycin treatment, at the time of the highest ARG expression in the 
lung: 104,4 ± 7,5 pmol L-arginine/mg protein versus 965,9 ± 208,8 pmol L-arginine/mg 
protein in lungs from mice subjected to bleomycin for 7 days and controls, respectively. 
L-arginine levels gradually increased after day 7, but remained decreased even 21 days 
after bleomycin treatment, compared with controls. 
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Figure 4.7. Levels of free cellular L-arginine during bleomycin-induced lung 
fibrosis. 
(A) Representative HPLC chromatograms illustrating free L-arginine levels in mouse 
lung homogenates from control versus three and seven days after bleomycin 
administration. (B) Concentration of free L-arginine in lung homogenates (n=6, 
*, p < 0,001), statistical analysis included two-tailed t-test.  
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4.1.6. Localization of arginase-1, -2 in the lung during lung fibrosis 
Previous results displayed an increase in ARG isoenzyme expression in total lung 
homogenates from bleomycin-treated mice. In order to verify ARG expression patterns in 
lung tissue, immunohistochemistry was performed on the sections obtained from control 
and bleomycin-treated mice for seven and fourteen days (Figure 4.8.). Moreover, it was 
examined whether the expression is specifically localized to particular cell types in the 
mouse lung.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8. Localization of ARG1 and ARG2 in mouse lung sections. 
Paraffin-embedded sections prepared from the lungs of control and bleomycin-treated 
mice for seven and fourteen days stained for ARG1, ARG2, and α-smooth muscle 
actin (SMA).  
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In accordance with previous reports 111, ARG1 was localized to macrophages and 
inflammatory regions, whereas ARG2 was present in bronchial epithelial cells. This 
localization pattern was mostly observed in the sections obtained from animals sacrificed 
seven days after drug administration. These results are of importance since the first week 
after bleomycin administration is described to be the inflammatory phase preceding 
fibrogenesis. Moreover, both ARG1 and ARG2 also exhibited the expression in fibrotic 
foci, which was seen fourteen days after drug administration, the period where the 
fibrogenic processes start. No expression of either isoeznyme was observed in control 
animals. 
 
 
4.2. Expression of arginase-1, -2 in fibroblasts 
4.2.1. Arginase-1, -2 expression in primary mouse fibroblasts 
Both ARG1 and ARG2 have been reported to be highly expressed in alveolar 
macrophages and immune cells during lung inflammation 104,115. As 
immunohistochemical results indicated the localization of ARG isoenzymes in lung 
fibrotic foci, further investigations were performed in order to examine expression of 
these enzymes in mouse primary lung fibroblasts - the key cell type responsible for 
increased collagen deposition during lung fibrosis. Therefore, isolation of mRNA as well 
as proteins was carried out using primary fibroblasts derived from the lungs of control 
and bleomycin-treated mice for 7, 14 and 21 days. The mRNA expression analysis was 
performed by means of semi-quantitative and quantitative RT-PCR (Figure 4.9.). 
The results were verified by analysis of protein expression levels by immunoblotting 
(Figure 4.10.). Both ARG1 and ARG2 expression was detectable in normal lung 
fibroblasts, and in accordance with previous results, both enzymes were significantly 
upregulated at the mRNA and protein levels in fibroblasts isolated from bleomycin-
treated mice. Interestingly, ARG1 expression was significantly enriched in fibroblasts, 
compared with lung homogenates. This was evident at the mRNA level, as well as at the 
protein level, suggesting an important role of ARG1 in this cell type. 
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Figure 4.9. ARG mRNA expression in primary mouse lung fibroblasts. 
ARG1 and ARG2 expression in lung primary fibroblasts isolated from control and 
bleomycin-treated mice for 7, 14 and 21 days analyzed by (A) semi-quantitative 
RT-PCR, (B) qRT-PCR. The GAPDH and PBGD genes served as control genes. Gels are 
representative for three independent experiments, (n=3, * p< 0,05), statistical analysis 
included two-tailed t-test.  
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Figure 4.10. ARG protein expression in primary mouse lung fibroblasts. 
ARG1 and ARG2 expression in lung primary fibroblasts isolated from control and 
bleomycin-treated mice for 7, 14 and 21 days analyzed by (A) IB. β-actin served as 
a protein loading control. (B) The results obtained by IB were densitometrically analyzed 
(n=3, * p< 0,05), statistical analysis included two-tailed t-test. 
 
4.2.2. Arginase-1, -2 immunolocalization in primary mouse fibroblasts 
To support previous observations, immunocytochemical staining was performed 
in mouse lung primary fibroblasts. Staining of ARG1 and ARG2 was performed by 
indirect immunofluorescence with rabbit anti-ARG1 and rabbit anti-ARG2 antibodies 
(Figure 4.11.). Both ARG isoenzymes displayed diffuse staining throughout the 
cytoplasm. Similar localization patterns of ARG isoenzymes were also observed in 
NIH-3T3 mice fibroblasts. 
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Figure 4.11. ARG localization in primary mouse lung fibroblasts. 
ARG1 and ARG2 localization visualized with secondary FITC-labelled antibody (green). 
Cell nuclei were visualized with DAPI (blue) in (A) mouse primary lung fibroblasts and 
(B) NIH-3T3 fibroblasts. 
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4.2.3. Induction of arginase-1, -2 expression by profibrotic agents 
Transforming growth factor-beta1 (TGF-β1) is the key profibrotic growth factor 
operative in lung fibrosis. Its presence leads to induction or altered expression of many 
genes in various diseases including lung fibrosis. In order to elucidate the regulatory 
mechanisms of ARG expression in lung fibrosis, an investigation was performed to 
examine whether TGF-β1 can alter ARG expression in a bleomycin-induced lung fibrosis 
model. Primary lung fibroblasts, derived from control mice, were stimulated with 
TGF-β1 (2 ng/ml) for up to 24 h, and mRNA expression was analyzed by 
semi-quantitative and quantitative RT-PCR (Figure 4.12.). The TGF-β1 rapidly increased 
ARG1 mRNA expression, as early as 2 h after treatment. Both ARG1 and ARG2 
expression was increased by up to eight-fold and two-fold, respectively, in response to 
TGF-β1, in primary mouse fibroblasts. 
A similar experiment was carried out in NIH-3T3 mice fibroblasts. Cells were 
stimulated with TGF-β1 (2 ng/ml) for up to 24 h, and mRNA isolation was performed in 
order to analyze the influence of this profibrotic agent on ARG expression by quantitative 
RT-PCR. In the line with results for primary cells, similar differences in TGF-β1-
dependent ARG1 expression were observed in NIH-3T3 fibroblasts, while ARG2 
decreased in this cell type. 
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Figure 4.12. TGF-β1–induced ARG expression in fibroblasts. 
ARG1 and ARG2 expression in mouse primary fibroblasts, stimulated with TGF-β1 for 
2, 6, 8, 12 and 24 h, analyzed by (A) semi-quantitative RT-PCR and (B) qRT-PCR. 
(C) Expression of both ARG in NIH-3T3 fibroblasts, stimulated with TGF-β1 for 2, 6, 8, 
12 and 24 h assessed by qRT-PCR. The GAPDH and PBGD genes served as control 
genes, (n=3, * p< 0,05), statistical analysis included two-tailed t-test. Gels are 
representative for three independent experiments. 
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4.3. Effect of arginase inhibitor on TGF-β1 signaling and 
extracellular matrix formation 
4.3.1. Arginase inhibition in NIH-3T3 fibroblasts 
4.3.1.1. Effect of arginase inhibition on TGF-β1-induced collagen deposition 
Increased collagen deposition, largely mediated by enhanced TGF-β1 signaling, 
represents the pathological hallmark of fibrosis 14. Previous results indicated that elevated 
activity of TGF-β1 in lung fibrosis leads to increased expression of ARG isoenzymes 
which may suggest the involvement of these enzymes in collagen production. Therefore, 
an investigation was performed to determine collagen deposition in the presence of the 
ARG inhibitor NG-hydroxy-L-arginine (NOHA) in NIH-3T3 fibroblasts. Cells were 
stimulated with TGF-β1 (2 ng/ml) for up to 24 h, and cellular collagen content was 
analyzed by Sircol assay (Figure 4.13.). The TGF-β1-induced increase in collagen 
production was completely attenuated by ARG inhibition, using NOHA at concentrations 
from 100 to 500 µM. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13. Regulation of collagen deposition by NOHA in NIH-3T3 fibroblasts. 
Alterations to collagen levels in NIH-3T3 fibroblasts upon TGF-β1 stimulation in the 
presence or absence of an arginase inhibitor, (n=3, * p< 0,05), statistical analysis included 
two-tailed t-test. 
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4.3.1.2. Effect of arginase inhibition on TGF-β1 signaling 
In order to estimate whether the inhibitory effect of NOHA on collagen deposition 
was due to blocking of TGF-β1 signaling, a luciferase assay was performed 
(Figure 4.14.). The NIH-3T3 cells were transfected with a luciferase reporter plasmid 
pCAGA12-luc or with pGL3-control, and stimulated with TGF-β1 alone or TGF-β1 in 
combination with NOHA, at a concentration of: 20 µM, 100 µM, 500 µM.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14. TGF-β1 signaling in the presence of NOHA in NIH-3T3 fibroblasts. 
The effect of NOHA on TGF-β1 signaling assessed on (A) baseline and (B) TGF-β1-
induced pCAGA12-luc expression. Luciferase expression plotted in relative Luciferase 
units corrected for transfection efficiencies (n=6, * p< 0,05), statistical analysis included 
two-tailed t-test. 
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The results obtained indicate that decreased collagen deposition in the presence of 
ARG inhibitor was not due to a general inhibitory effect of NOHA on TGF-β1 signaling, 
since the Smad-driven reporter gene expression of pCAGA12-luc remained unchanged in 
the presence of this inhibitor. 
 
 
4.3.1.3. Effect of arginase inhibition on extracellular matrix components expression 
To further investigate the effects of NOHA, it was investigated whether an ARG 
inhibitor can affect the expression of ECM components. The NIH-3T3 cells were 
stimulated with TGF-β1 for up to 24 h in the presence or absence of NOHA. 
Subsequently, mRNA was isolated and expression levels of collagen 1A1 (COL1A1) and 
α-sooth muscle actin (α-SMA) were examined using quantitative RT-PCR (Figure 4.15.). 
Although previous data indicated NOHA inhibitory influence on collagen deposition, 
interestingly, in this experiment NOHA did not display any influence on collagen and 
smooth muscle actin mRNA levels. This result suggests NOHA functions at a 
post-transcriptional level in the examined cell type.  
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Figure 4.15. Influence of NOHA on expression of ECM components by NIH-3T3 
fibroblasts. 
The effect of NOHA on (A) COL1A1 and (B) α-SMA mRNA expression in NIH-3T3 
fibroblasts determined by qRT-PCR. The PBGD gene served as a control gene, (n=3, 
* p< 0,05), statistical analysis included two-tailed t-test. 
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4.3.2. Arginase inhibition in human primary fibroblasts 
Although the ARG inhibitor NOHA exhibited a strong effect on collagen 
deposition in NIH-3T3 fibroblasts, further investigation was required in order to verify 
whether NOHA displayed a similar influence on human primary fibroblasts.  
 
4.3.2.1. Effect of arginase inhibition on TGF-β1-induced collagen deposition 
Human primary lung fibroblasts, derived from healthy transplant donors, were 
stimulated with TGF-β1 alone or TGF-β1 in combination with NOHA. Subsequently, 
cellular collagen content was analyzed by Sircol assay (Figure 4.16.). In agreement with 
the observations made for mouse NIH-3T3 fibroblasts, NOHA at concentrations 500 µM 
completely abolished TGF-β1-induced increase in collagen production.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.16. Effect of NOHA on collagen deposition by human primary fibroblasts. 
Alterations to collagen levels in human primary lung fibroblasts assessed upon TGF-β1 
stimulation in the presence or absence of NOHA, an arginase inhibitor, (n=3, * p< 0,05), 
statistical analysis included two-tailed t-test. 
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4.3.2.2. Arginase inhibitor effect on expression of extracellular matrix components 
Levels of COL1A1 and α-SMA mRNA expression were examined by quantitative 
RT-PCR upon stimulation of human primary lung fibroblasts with TGF-β1 alone or 
TGF-β1 in combination with NOHA (Figure 4.17.). In line with results obtained for 
NIH-3T3 fibroblasts, mRNA levels of COL1A1 and α-SMA in human primary lung 
fibroblasts were not affected in the presence of ARG inhibitor, which further supports the 
assertion that NOHA exhibits regulatory effects at the translational level. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.17. Effect of NOHA on expression of ECM components by human 
primary fibroblasts. 
The effect of NOHA on (A) COL1A1 and (B) α-SMA mRNA expression in human 
primary lung fibroblasts determined by qRT-PCR. The PBGD gene served as a control 
gene, (n=3, * p< 0,05), statistical analysis included two-tailed t-test. 
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4.4. Arginase-1, -2 in idiopathic pulmonary fibrosis 
Since ARG1 and ARG2 were upregulated in bleomycin-induced lung fibrosis in 
mice, additional experiments were conducted in order to determine if the expression 
levels of these enzymes differ in human pathological conditions. For this purpose, the 
expression, localization and activity of ARG isoenzymes were assessed in human IPF and 
donor lungs. 
 
4.4.1. Arginase-1, -2 localization in human lungs 
To examine whether ARG isoenzymes specifically localize to particular human 
cell types, immunohistochemistry was performed on the lung sections obtained from IPF 
patients and transplant donors (Figure 4.18.). Contrary to the results obtained for mice 
lung sections, both ARG1 and ARG2 exhibited strong staining in lungs from donors. 
Both enzymes were localized in bronchial epithelial cells, interestingly, strong staining 
for ARG1 was detected on cilia of the epithelial cells of healthy donors. In IPF patients  
ARG1 was observed to some extent in fibroblasts, but the signal in bronchial epithelial 
cells remained limited to the cilia. In contrast to bleomycin model, ARG2 exhibited clear 
distribution in alveolar epithelial type II cells in IPF. 
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Figure 4.18. Localization of ARG1 and ARG2 in human lung sections. 
Paraffin-embedded sections prepared from the lungs of healthy transplant donors and IPF 
patients stained for (A) α- SMA, and (B) ARG1, ARG2.  
 
 
A
R
G
1 
A
R
G
2 
IPF 
A
R
G
1 
A
R
G
2 
DONOR 
B. 
Results  65 
 
4.4.2. Arginase-1, -2 expression in human lungs 
To further verify the expression of ARG1 and ARG2 in human lung tissue, 
mRNA isolation was performed from lung tissue of transplant donors and IPF patients. 
Quantification of mRNA levels was conducted by means of quantitative RT-PCR 
(Figure 4.19.). 
Interestingly, the results obtained for human samples did not follow the pattern 
observed in bleomycin-induced lung fibrosis. Although in donors the enzymes exhibited 
low expression levels, which is in accordance with the results from unchallenged mice, 
no elevated ARG mRNA levels were observed in IPF patients. Moreover, ARG1 
displayed decreased levels in IPF patients.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.19. ARG mRNA expression in human lung homogenates. 
ARG1 and ARG2 mRNA expression in human lung from transplant donor versus IPF 
patients analyzed by qRT-PCR. The PBGD gene served as a control gene, (n=3), 
statistical analysis included two-tailed t-test 
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4.4.3. Arginase-1,-2 activity in human lungs 
Since mRNA levels do not necessary correlate with cellular protein levels and 
enzymatic activity, further studies were carried out in order to determine the activity of 
ARG isoenzymes in human lung tissue. For this purpose, lung homogenates were 
prepared from donors and IPF patients, and quantification of ARG activity was conducted 
with the QuantiChrom™ Arginase Assay Kit (Figure 4.20.). In line with previous 
experiments, no significant difference in ARG activity was observed in IPF patients 
versus donors.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.20. ARG activity in human lung homogenates. 
Arginase activity in human lung from healthy donor transplant versus IPF patients 
analyzed by Arginase Assay Kit, (n=3), statistical analysis included two-tailed t-test  
A
rg
in
a
se
 
a
ct
iv
ity
 
(U
/l)
 
DONOR IPF 
0
2
4
6
8
10
12
Discussion  67 
 
5. Discussion 
5.1. Involvement of arginase-1, -2 in lung diseases 
Recently, several reports have shown an interest in ARG expression and activity, 
as these enzymes affect L-arginine bioavailability for NOS 116, and impact several lung 
diseases, such as asthma 117 and cystic fibrosis 107. Interestingly, ARG-mediated 
attenuation of NO production by constitutive NOS was linked to airway 
hyperreactivity 118, which could be reversed by pharmacological inhibition of ARG 119. 
Apart from NO synthesis, ARG can also directly influence collagen metabolism, as its 
product, L-ornithine, is metabolized to polyamines and L-proline, the latter being highly 
enriched in collagen. Thus, ARG expression and activity may significantly impact 
pathophysiologic mechanisms involved in lung fibrosis, including increased collagen 
synthesis due to augmented L-proline bioavailability, endothelial dysfunction of the 
pulmonary vascular bed due to decreased NO synthesis, and higher cell proliferation 
induced by enhanced bioavailability of polyamines.  
 
5.2. Arginase isoenzymes in an animal model of lung fibrosis 
5.2.1. Arginase-1, -2 expression pattern 
In the present study, the well-established model of bleomycin-induced lung 
fibrosis in mice was used in order to analyze in detail the regulation of L-arginine 
metabolism in this lung disorder. The salient finding of this study was a significant 
upregulation of ARG1 and ARG2 expression in fibrotic lungs (Figure 4.4.), particularly 
evident seven and fourteen days after bleomycin administration. More detailed analysis 
of ARG isoenzyme expression revealed that, as early as three and five days after drug 
administration, an upregulation of ARG isoenzymes at the mRNA (Figure 4.5.) and 
protein levels (Figure 4.6.) was detected. These data confirmed results from an earlier 
study 111, which indicated an upregulation of ARG and ODC mRNA, and ARG1 and 
ARG2 protein in lung homogenates of bleomycin-treated mice. Similar to data presented 
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in our project, ARG1 protein expression was also undetected in lung homogenates from 
control mice, but was present after seven days of bleomycin treatment. In contrast to this 
study, we detected ARG2 protein in lungs from control mice, while this was not the case 
in the cited study. Interestingly, the expression levels of cationic L-arginine transporters 
(Figure 4.1.) and other enzymes of arginine metabolism (Figure 4.3., and Figure 4.4.), 
with the exception of iNOS, remained unchanged during lung fibrosis. The iNOS 
expression displayed a progressive increase during the development of lung fibrosis. 
Increased ARG expression during lung fibrosis was of functional relevance, as it 
correlated with decreased levels of free lung cellular L-arginine (Figure 4.7.). The highest 
depletion of the amino acid was observed seven and fourteen days after drug 
administration. It is well-established that IPF may be affected by Th2-mediated 
inflammation, which leads to progressive deposition of ECM, fibrogenesis, and 
destruction of the pulmonary parenchyma. Similar patterns can be observed in a 
bleomycin-induced lung fibrosis model, where approximately seven days after drug 
administration, a strong inflammatory response is evident, followed by the onset of 
fibrosis two weeks after treatment with bleomycin. Recently, it has been also 
demonstrated that iNOS and ARG activities can be differentially modulated by Th1 and 
Th2 cells and their cytokines 103. Th1 cytokines (e.g. INF-γ) activate iNOS 120, whereas 
Th2 cytokines (e.g. IL-4, IL-13) promote ARG activity 121. Thus, the upregulation of the 
ARG expression observed during bleomycin-induced lung fibrosis may be explained by 
the fact that mice inflammatory response is dominated by the production of 
Th2-associated cytokines, including IL-4, IL-5, IL-10 and IL-13. 
 
5.2.2. Cellular localization of arginase-1, -2 
Both ARG1 and ARG-2 were reported to be ubiquitously expressed in various 
tissue types. Despite their similarity concerning enzymatic properties, they differ with 
regard to subcellular localization and tissue distribution. The ARG1 is cytosolic enzyme, 
highly expressed in the liver, whereas ARG2 is enriched in mitochondria, and displays 
expression in organs such as the kidney, brain, small intestine, or mammary glands 70. 
Immunohistochemical data presented in our project indicated the expression of both 
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ARG1 and ARG2 in lung sections from mice treated with bleomycin, seven and fourteen 
days after drug administration. The ARG was localized in areas of increased 
inflammation, as well as in fibrotic lesions (Figure 4.8.). These results are in accordance 
with in vitro experiments demonstrating that several Th2-associated cytokines are 
involved in the generation of alternatively activated macrophages, characterized by up-
regulation of ARG1 122,123. Further confirmation of the immunohistochemical results was 
obtained by the analysis of ARG expression in primary lung fibroblasts isolated from 
animals treated with bleomycin for different time points (Figure 4.9., and Figure 4.10.). 
Both ARG1 and ARG2 were highly expressed in fibroblasts, and their expression was 
increased in fibroblasts derived from bleomycin-treated mice compared with controls. 
In healthy mouse lungs, ARG1 and ARG2 mRNA were expressed at similar levels, but 
ARG2 protein could be detected at higher levels than ARG1 (Figure 4.6.). In contrast, in 
primary lung fibroblasts, ARG1 mRNA was expressed at higher levels than ARG2, and 
was also regulated much more potently by bleomycin treatment in vivo, as demonstrated 
by quantitative RT-PCR (Figure 4.9.), and immunoblotting analysis (Figure 4.10.). 
These results are in agreement with data reporting that proinflammatory cytokines 
IL-4 and IL-13 appear to be important regulatory mediators for ARG in airway rat 
fibroblasts, since they caused significant upregulation of these enzymes 124. Additionally, 
ARG1 expression was also detected by immunohistochemical staining in interstitial 
fibroblasts in Herpes virus-induced lung fibrosis 110. Nevertheless, results presented in 
our project are of high importance, as they directly indicate upregulation of ARG 
isoforms and quantify expression of these enzymes in the primary lung fibroblasts 
derived from bleomycin- and saline-treated mice. 
 
5.2.3. Regulation of arginase-1, -2 by profibrotic factors 
5.2.3.1. TGF-β1-mediated arginase expression 
It is well established that TGF-β plays an important role in the process of wound 
healing and fibrosis 125. This multifunctional peptide is capable of enhancing proliferation 
of mesenchymal cells and synthesis of ECM. It has been also reported that TGF-β 
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contributes to early events that lead to bleomycin-induced pulmonary fibrosis. 
Mammalian TGF-β exists in three isoforms 126 (TGF-β1, TGF-β2, TGF-β3), all of which 
were shown to be present in the normal lung. However, it was demonstrated that TGF-β 
isoform gene expression can be differentially controlled during experimental pulmonary 
fibrosis, with TGF-β1 being the predominant isoform expressed during the pathogenesis 
of lung fibrosis 127. In the present project, it was demonstrated that TGF-β1 potently 
induced ARG1 expression in lung fibroblasts (Figure 4.12.). This interesting result is in 
agreement with studies demonstrating TGF-β-induced ARG activity in macrophages 128. 
The TGF-β is one of the most important cytokines in wound healing, as it leads to 
increased deposition of collagen by stimulated fibroblasts, moreover it was reported to 
induce the inhibition of NO production by macrophages through decreasing the stability 
and translation of mRNA for NOS and increasing its degradation 129. The NO, a highly 
reactive free radical with pleiotropic effects, was demonstrated as a potentially important 
antifibrotic molecule in the regulation of wound healing 130,131. Moreover, there are 
studies indicating NO-dependent suppression of TGF-β expression 132. Thus, the results 
presented in this project connected with the possible imbalance in L-arginine/NO 
pathway caused by overexpression of TGF-β, suggest that ARG1 may be a key enzyme 
influencing collagen synthesis in fibroblasts. 
 
5.2.3.2. Arginase-dependent collagen synthesis 
In order to analyze whether ARG1 can affect the process of lung fibrosis and 
collagen synthesis, further experiments were performed. Based on the results presented in 
our project and published data, it can be argued that arginine depletion by increased ARG 
expression can affect cell and lung functions in several ways: on the one hand, the 
dramatic reduction of free L-arginine leads to its decreased bioavailability for NOS, thus 
leading to decreased NO production, as was demonstrated in detail in macrophages and 
epithelial cells 133,134. Although ARG isoenzymes have a significantly lower Km for 
L-arginine, they exhibit a 1000× higher Vmax compared with NOS, as such having the 
capacity to functionally inhibit NOS via substrate depletion 74. Reduced NO levels, on the 
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other hand, have been shown to lead to airway and vascular smooth muscle cell 
proliferation, as well as enhanced susceptibility to pulmonary infections 87, features 
occurring in pulmonary fibrosis. Next, and probably much more important, augmented 
generation of L-ornithine by ARG increases the bioavailability of polyamines and 
L-proline, essential regulators of cell proliferation and collagen synthesis, respectively 49. 
Since fibroblast proliferation and collagen accumulation are hallmarks of lung fibrosis, 
this pathway could present an attractive option for therapeutic intervention. To elucidate 
the possible impact of ARG activity on collagen synthesis and deposition, experiments 
with the ARG inhibitor NG-hydroxy-L-arginine, NOHA, were performed. Inhibition of 
ARG activity using NOHA significantly attenuated TGF-β1-induced collagen deposition 
in NIH-3T3 cells (Figure 4.13.), as well as in primary human lung fibroblasts 
(Figure 4.16).  
This presents strong evidence that ARG1 is the key enzyme influencing collagen 
synthesis in fibroblasts. These results are in agreement with recently published data 
indicating that ARG plays an important role in the pathophysiology of transplant-related 
pulmonary fibrosis. Here, it was demonstrated that downregulation of ARG protein 
expression and a reduction of ARG activity is a central mechanism for the protective role 
of pirfenidone, an antifibrotic agent with no immunosuppressive effect, in transplant-
related pulmonary fibrosis 135. 
Additional experiments were performed in order to test whether NOHA has an 
effect on fibroblast ECM gene expression (Figure 4.15. and Figure 4.17.). Interestingly, 
these results revealed no regulation of COL1A1 and α-SMA gene expression in presence 
of NOHA. Thus, these data strengthen the argument that ARG inhibition blocks ECM 
deposition by acting on its biosynthesis in a post-transcriptional manner. 
 
5.2.3.3. Influence of arginase on TGF-β1 signaling 
As TGF-β1 is an important mediator in the pathogenesis of fibrosis, it is also 
important to examine downstream events of its activity, such as intracellular signaling. 
The active form of TGF-β binds to the type II TGF-β receptor (TGF-βRII), which leads 
to the assembly of a heterotertrameric complex of TGF-βRII and TGF-βRI, both of 
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which are transmembrane serine/theronine kinase receptors. The TGF-βRI is also known 
as activin-like kinase 5 (ALK5), and within this heteroterameric complex, the kinase 
domain of ALK5 is phosphorylated by TGF-βRII. Subsequently, ALK5 phosphorylates 
and activates the intracellular receptor-activated Smad proteins (Smad2 and Smad3). 
These proteins interact with Co-Smad, Smad4, to enter the nucleus and modify 
transcription of a series of genes involved in matrix expression, cell differentiation, and 
proliferation 135. 
In the absence of Smad3, ALK5 cannot transmit signal through to the nucleus and 
thus cannot upregulate expression of matrix genes in either bleomycin or TGF-β-
mediated fibrotic stimulation 136,137. In other words, these data indicate that the 
progressive nature of fibrosis can proceed only in the presence of intact TGF-βRI 
signaling mechanism and/or intact Smad3 signaling.  
To further test the influence of ARG inhibition on TGF-β signaling, fibroblasts 
were transfected with the pCAGA12 luciferase reporter plasmid, and incubated with the 
ARG inhibitor NOHA. The effect of NOHA on TGF-β1-dependent signaling was studied 
(Figure 4.14.). Our results indicated that NOHA did not exert any effect on TGF-β1 
signaling, as the Smad-driven reporter gene expression of the pCAGA12-luc remained 
unchanged in the presence of this inhibitor. Interestingly, although ARG inhibition was 
able to attenuate collagen synthesis, it did not inhibit TGF-β1 signaling, as such 
exhibiting pathway specificity, and the perspective of modulating collagen metabolism, 
but leaving unaffected the potent anti-inflammatory properties exerted by TGF-β1. 
 
 
5.3. Limitations of the bleomycin model of lung fibrosis 
Idiopathic pulmonary fibrosis is a chronic interstitial lung disorder of unknown 
etiology. It is characterized by progressive parenchymal fibrosis and ventilatory 
restrictions. Although the pathogenesis of this disease is complex and poorly understood, 
it has been suggested that inflammation does not play a major role in initiating this 
disorder. According to a number of recently published data, IPF represents an 
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epithelial/fibroblastic disorder. This hypothesis suggests that epithelial injury and 
activation, rather than alveolitis, represent a key factor in the pathogenesis of IPF. Over 
the last years, the bleomycin model of pulmonary fibrosis has been most commonly 
studied in order to elucidate the regulatory mechanisms in pulmonary fibrogenesis. 
Intratracheal instillation of bleomycin leads to pulmonary fibrosis, which partly 
resembles human fibrotic lung disease. These characteristics include patchy parenchymal 
inflammation of variable intensity, epithelial cell injury with reactive hyperplasia, 
basement membrane damage, and interstitial as well as intraalveolar fibrosis. Despite 
these similarities, several issues have been raised regarding the validity of the bleomycin 
model. The main concerns relate to the speed of disease onset, as lung remodeling is 
much accelerated in this model, and to the durability 138. Generally, bleomycin-induced 
pulmonary fibrosis in mice is almost complete within the fourth week after administration 
of the drug. During the acute stage of the disease, approximately two weeks after drug 
instillation, acute lung injury is a predominant feature of this model. As a result of this 
lung injury, remodeling of normal alveolar structure occurs during the chronic stage of 
the disease. Moreover, animals treated with bleomycin exhibit inflammation at early 
stages, from three days post-instillation to late stages such as 14–21 days after drug 
administration, where it coincides with lung fibrosis. In addition, bleomycin-induced 
fibrosis is reversible, and as such, is difficult to compare with IPF. 
Thus, all traditional models of IPF start with inflammation, and with unknown 
etiology, there is no appropriate experimental model available. Nevertheless, it has to be 
considered that the main discrepancies between the bleomycin model and human IPF 
relate to the chronic stages of the disease, as such bleomycin model still represents an 
important tool to test molecular mechanisms involved in IPF pathogenesis. 
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5.4. Arginase-1, -2 in idiopathic pulmonary fibrosis 
5.4.1. Arginase-1, 2 localization in human lung tissues 
To investigate whether ARG isoenzymes displayed a pattern of localization in 
human lung tissue similar to the mouse model, immunohistochemical staining was 
performed on human lung sections from control transplant donors and IPF patients 
(Figure 4.18.). Interestingly, both ARG isoforms were detected in IPF patients as well as 
in healthy controls, in contrast to the bleomycin model, where ARG signal was 
undetected in control animals. The ARG1 was detected in epithelial cells in donors 
tissues, whereas in IPF patients, localization of this enzyme was strong in bronchial 
epithelial cells where it was confined to cilia of these cells. Additionally, inflammatory 
cells like macrophages exhibited positive staining for ARG1, which confirms the function 
of this enzyme in inflammatory reactions in the airways 117. Similar to ARG1, ARG2 
exhibited localization in bronchial epithelial cells in donor lung tissue, but unlike ARG1, 
it was undetected within the cilia of these cells. Interestingly, lung sections from IPF 
patients, ARG2 was detectable in alveolar epithelial type II cells. Moreover, both 
enzymes exhibited to some extent, localization within fibrotic lesions, in agreement with 
previously reported results indicating ARG localization in areas with pleural thickening, 
interstitial fibrosis, and epithelial cells 110. 
 
5.4.2. Expression of arginase-1, -2 in human lung tissues 
Interestingly, differences in ARG localization between donors and IPF patients 
were not as prominent as in the bleomycin-induced fibrosis model. It has to be 
considered, however, that immunohistochemistry is not a quantitative method of protein 
expression. Therefore, further analysis of ARG expression in the lungs of donors and IPF 
patients was performed using quantitative RT-PCR (Figure 4.19.). In line with results 
obtained for control animals, mRNA levels of ARG isoforms were low in healthy donors, 
but, no increased expression was observed in the lungs of IPF patients. Conversely, 
ARG1 demonstrated even lower mRNA levels in the lungs of IPF patients. These results 
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contrast with data indicating an upregulation of ARG1 expression in IPF patients at the 
protein level 110. To confirm these expression results, analysis of ARG activity in donors 
and in IPF patients was performed (Figure 4.20.). In agreement with mRNA expression 
data presented in our project, there was no significant induction of ARG activity in lungs 
of IPF patients in comparison to lungs from healthy transplant donors. Since very little is 
known about ARG regulation in human lung tissue, and published data remain 
contradictory, it would be of benefit to further investigate this issue in future studies. 
 
5.5. Conclusions and future perspectives 
L-arginine serves as a substrate for both ARG and NOS. The pathways of these 
two enzymes can therefore interfere with one another through substrate competition 52. 
The NO can regulate a number of aspects of human airway biology, including airway and 
vascular smooth muscle tone 139, whereas elevations of ARG levels accompany a variety 
of pathological states, including pulmonary diseases such as asthma, silicosis, or 
pulmonary hypertension. Interestingly, it became apparent that cytokines, for instance 
IL-4 or IL-13, which are implicated in various lung disorders, also behave as inducers of 
ARG, and contribute to the increase in enzyme levels observed in these diseases.  
In this investigation, we hypothesized that L-arginine metabolizing enzymes are 
altered in pulmonary fibrosis. In order to explore this idea, an initial characterization of 
enzyme expression was performed in the mouse model of bleomycin-induced lung 
fibrosis. The upregulation of ARG1 and ARG2 in fibrotic lungs was demonstrated, which 
correlated with decreased levels of L-arginine in the lung. Both ARG isoforms were 
localized to fibrotic lesions, and highly expressed in primary lung fibroblasts derived 
from bleomycin-treated mice. It was also reported that TGF-β1, a key profibrotic 
mediator, potently induced ARG expression in lung fibroblasts. Additionally, it was 
demonstrated that the ARG inhibitor has a potent inhibitory effect on TGF-β1-induced 
collagen deposition by mouse and human fibroblasts. 
Experiments performed on human lung tissues from control transplant donors and 
IPF patients, however, did not fully support the results obtained from the animal model of 
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lung fibrosis. The discrepancy between these results for human disease and animal 
model, however, can be explained. First, significant changes in ARG expression, as well 
as in free L-arginine levels in the animal model of fibrosis were observed during the 
inflammatory and early fibroproliferative phase of the disease, which corresponds to the 
first and second week after bleomycin instillation. This may suggest the involvement of 
ARG isoenzymes in the early stages of the disease, which until now are difficult to 
recognize in IPF, as early detection of this disease remains difficult. It cannot be excluded 
that the levels of ARG are connected with progression of pulmonary fibrosis. Second, it 
remains difficult to compare gene expression results for humans and mice, as tissues from 
IPF are often difficult to obtain. Moreover, the animal model of lung fibrosis allows the 
generation of material of high reproducibility, whereas incomplete patients history often 
contributes to a high level of heterogeneity of human material. In order to elucidate this 
issue, and to minimize ambiguous results, further investigations should be performed in 
the future, possibly entailing more diseases such as COPD (chronic obstructive 
pulmonary disease) and asthma.  
Since inhibition of ARG activity significantly attenuated TGF-β1-induced 
collagen deposition in primary human lung fibroblasts, it would be of benefit to 
investigate ARG expression in other cell types isolated from IPF patients or healthy 
donors. Methods such as microdissection would be a useful tool to collect material not 
only from lung fibroblasts, but also from epithelial cells, as they expressed ARG in lungs 
from IPF patients. Furthermore, this would clarify whether manipulation of ARG activity 
in pulmonary fibrosis offers the intriguing possibility of interfering with the development 
of the disease. It also has to be considered that unrestricted pharmacological inhibition of 
ARG with the usage of compounds like NOHA can alter the liver urea cycle function and 
can cause hepatotoxicity. Therefore, reliable methods should be developed to induce the 
loss of ARG function specifically in the lung, such as localized delivery of short-lived, 
reversible inhibitors of arginase.  
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6. Appendix 
6.1. List of primers used for PCR amplification 
6.1.1. Quantitative RT-PCR 
 
Quantitative RT-PCR 
GeneBank™ 
Accession 
number 
Forward Primer  
(5′-3′) 
Reverse Primer  
(5′-3′) 
Annealing 
temperature 
(°C) 
Amplicon size 
(bp) 
ARG1 mouse 
NM_007482.2 
GGAACCCAGAGAGAG
CATGA 
TTTTTCCAGCAGACCA
GCTT 60 132 
ARG1 human 
NM_000045.2 
CTACAAAACAGGGCTA
CTCTCAGGAT 
GTTCGAGTTACTTCTTC
TGGTGTCTTC 60 83 
ARG2 mouse 
NM_009705.1 
ACCAGGAACTGGCTGA
AGTG 
TGAGCATCAACCCAGA
TGAC 60 141 
ARG2 human 
NM_001172.3 
AGAAAAGGAGTGGAG
CATGG 
GATCATCTTTGGGGAC
TGGA 60 126 
COL1A1 mouse 
NM_007742.2 
ACGTCCTGGTGAAGTT
GGTC 
TCCAGCAATACCCTGA
GGTC 59 117 
COL1A1 human 
NM_000088.2 
CCAGAAGAACTGGTAC
ATCAGC 
CGCCATACTCGAACTG
GAAT 59 94 
PBGD mouse 
NM_013551.1 
ATGTCCGGTAACGGCG
GC 
GGTACAAGGCTTTCAG
CATCG 60 138 
PBGD human 
NM_000190.3 
CCCACGCGAATCACTC
TCAT 
TGTCTGGTAACGGCAA
TGCG 60 69 
α-SMA mouse 
NM_007392.2 
CTGACAGAGGCACCAC
TGAA 
CATCTCCAGAGTCCAG
CACA 59 159 
α-SMA human 
NM_001613.1 
GAGAAGAGTTACGAGT
TGCCTG 
TGTTAGCATAGAGGTC
CTTCCTG 59 180 
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6.1.2. Semi-quantitative RT-PCR 
 
Semi-quantitative RT-PCR 
GeneBank™ 
Accession 
number 
Forward Primer  
(5′-3′) 
Reverse Primer  
(5′-3′) 
Annealing 
temperature 
(°C) 
Amplicon size 
(bp) 
ADC mouse 
NM_172875.1 
GACTTTGTGATGGTGG
AGGAG 
GAGGCAGGTGCTTCAG
AAAG 58 148 
ARG1 mouse 
NM_007482.2 
AAGCTGGTCTGCTGGA
AAAA 
CTGGTTGTCAGGGGAG
TGTT 60 310 
ARG2 mouse 
NM_009705.1 
TGGGATGCCACCTAAA
AGAC 
CCTGGCAGTTGTGGTA
CCTT 60 358 
DDAH1 mouse 
NM_026993.1 
CAAATCAACGAGGTGC
TGAA 
TGCGCTTTCTGGGTAC
TCTT 58 302 
DDAH2 mouse 
NM_016765.1 
ACTTGGGACTCCGAAT
TGTG 
CATCTGGGAGGGTCAG
AGAG 58 318 
GAPDH mouse 
XR_001547.1 
AACTTTGGCATTGTGG
AAGG 
ACACATTGGGGGTAGG
AACA 59 223 
OAT mouse 
NM_016978.1 
GGTGCACACAATTACC
ATCCT 
CTTGGCTGACAGCACC
ATAA 58 121 
ODC mouse 
NM_013614.1 
TTTGACTGCCACATCC
TTGA 
CGAGGTCCGCAACATA
GAAC 58 112 
PRMT1 mouse 
NM_019830.1 
CACCCTCACATACCGC
AACTCC 
CAGCCACTTGTCCCGA
GCGT 60 339 
PRMT2 mouse 
NM_133182.1 
CGACAAGCAACTGGA
GGAATAC 
ACCTTCTCGGGCAGCA
CCAC 60 359 
PRMT3 mouse 
NM_1133740 
TTGCACCATCAGCCTT
GTAT 
GACCCTGTTGTGGCAA
TTCT 60 316 
PRMT4 mouse 
NM_021531.2 
CACCCCACGATTTCTG
TTCT 
CTCTTCACCAGGACCT
CTGC 60 346 
PRMT5 mouse 
NM_013768.1 
CAGGCTGTATGCTGTG
GAGA 
GCATCTCAAACTGTGC
CTCA 60 344 
PRMT6 mouse 
NM_178891.3 
TATGGCGTGGATATGA
GCTG 
CCGGAAATGTCCGTAT
CTTG 60 374 
PRMT7 mouse 
NM_145404.1 
ATTGCCAGGTCATCCT
ATGC 
CAAACAGCTCCGTGAT
CAGA 60 352 
NOS2 mouse 
NM_010927.1 
AGACCTCAACAGAGCC
CTCA 
GCAGCCTCTTGTCTTT
GACC 58 305 
NOS3 mouse 
NM_008713.2 
ATGTGCGCCCCTGTTA
CTC 
CACAGGGATGAGGTTG
TCCT 58 322 
SLC7A1 mouse 
NM_007513.2 
TGGCTGGAACTTGATT
CTCT 
ACGTGAGAACTCTCCG
ATGG 59 109 
SLC7A2 mouse 
NM_007514.2 
TTGCCGTGTGCCTTGT
ATTA 
CAGCCACCATGACAAA
GAGA 59 123 
SLC7A4 mouse 
NM_144852.2 
TTCTACAGGCGGGGTT
ACAG 
GGCAAACACCTGGAA
GAAGA 59 150 
SLC7A5 mouse 
NM_011404.2 
TGGTCTTCGCCACCTA
CTTG 
AAGCCGAGCAAAATG
ATGAG 59 199 
SLC7A6 mouse 
NM_178798.2 
CCCACCTGTGATCCTC
CATA 
CCTTGGCATACGTGAA
TGTG 59 130 
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Semi-quantitative RT-PCR 
GeneBank™ 
Accession 
number 
Forward Primer  
(5′-3′) 
Reverse Primer  
(5′-3′) 
Annealing 
temperature 
(°C) 
Amplicon size 
(bp) 
SLC7A7 mouse 
NM_011405.1 
ATCCGCCTCTGGACTT
CTCT 
GTTCCCCACTTGACAT
AGGC 59 190 
SLC7A9 mouse 
NM_021291.1 
GAGACAAGCCTGAGG
AGACG 
ATGGTGCCCACAATGA
TACA 59 121 
SLC6A14 mouse 
NM_020049.2 
TCCAGTGAACCATGGA
CAGA 
AATCCCACTGCATAGC
CAAC 59 177 
 
 
6.2. List of antibodies 
6.2.1. Primary antibodies 
 
Antibody 
Dilution 
Primary Host 
IB IHCH ICCH 
Company 
anti - α-SMC mouse   1:500 Sigma-Aldrich 
anti - ARG1 mouse 1:1000   BD Transduction Laboratories 
anti - ARG1 rabbit  1:100 1:100 Santa-Cruz Biotech 
anti - ARG2 rabbit 1:1000 1:100 1:100 Santa-Cruz Biotech 
anti - β-actin rabbit 1:1000   Cell Signaling 
anti - PRMT1 rabbit 1:2000   Upstate 
anti - PRMT2 rabbit 1:1000 
  
Abcam 
anti - PRMT3 rabbit 1:2000   Upstate 
anti - PRMT4 rabbit 1:1000   Upstate 
anti - PRMT5 rabbit 1:2000   Upstate 
anti - PRMT6 rabbit 1:500   Imgenex 
anti - PRMT7 rabbit 1:500   Upstate 
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6.2.2. Secondary antibodies 
 
Antibody 
Dilution 
Secondary Host 
IB IHCH ICCH 
Company 
FITC-conjugated 
anti-mouse IgG goat   1:300 ZyMax 
FITC-conjugated 
anti-rabbit IgG goat   1:300 ZyMax 
HRP-conjugated 
anti-mouse IgG goat 1:3000   Pierce 
HRP-conjugated 
anti-rabbit IgG goat 1:3000   Pierce 
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